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Abstract 
 
Glioblastomas (GBMs) are the most common and malignant type of glioma, the majority subtype 
of primary brain tumors. Despite the therapeutic advances over the past years, the median overall survival 
of patients is only 15 months after diagnosis. The high degree of heterogeneity between GBMs leads to 
an unpredictable clinical outcome. The variety of complex components in the tumor microenvironment 
has been associated with the aggressiveness of GBMs and with the inefficacy of treatments currently 
available. Astrocytes, the major glial cell type in the brain, are usually associated with the regulation of 
brain homeostasis, being involved in distinct regulatory processes, as angiogenesis or blood brain barrier 
(BBB) regulation. In GBM, astrocytes have been shown to secrete factors/proteins that may to regulate 
tumor growth, invasion, and progression. This secretion is performed, among others, by SNARE-
dependent exocytosis, a mechanism impaired in astrocytes of the dnSNARE mouse model. By using this 
model, we explored the role of astrocytic exocytosis in the growth and invasion of GBM using in vitro and 
in vivo complementary approaches. We evaluated the effect of conditioned medium (CM), derived from 
wild – type (WT) and dnSNARE glial cultures, in the viability and migration of a glioma cell line. Moreover, 
using a syngeneic orthotopic glioma murine model (GL261), we evaluated the influence of astrocytic 
SNARE-dependent exocytosis in glioma growth in vivo and mice survival. The viability assays in vitro 
suggested a regulation of glioma cells by WT-derived CM, significantly increasing glioma cell viability, 
which was not significant when glioma cells were in contact with dnSNARE-derived CM. Concerning the 
in vivo results, our data suggest that the substances secreted by astrocytes appear to influence GBM 
behavior, leading to a decrease in mice survival. Interestingly, tumor size was similar in mice of both 
genotypes, suggesting other cancer hallmarks may be regulated in this GBM-astrocyte interaction. The 
results discussed in this thesis suggest that by releasing regulatory molecules, astrocytes might support 
GBM pathophysiology. The identification of the astrocyte-derived regulatory molecules may identify novel 
therapeutic targets for GBM treatment.  
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Resumo 
 
Os glioblastomas (GBMs) são o tipo mais comum e maligno de gliomas, o maior sub-tipo de tumor 
primário no cérebro. Apesar dos avanços terapêuticos nos últimos anos, o tempo médio de sobrevivência 
dos pacientes depois de diagnosticados, é de apenas 15 meses. O elevado grau de heterogeneidade 
entre GBMs encontra-se relacionado com a imprevisibilidade no desenrolar desta doença. A variedade 
de células no microambiente tumoral tem sido associada com a agressividade apresentada por estes 
tumores e pela ineficácia dos tratamentos actualmente disponíveis. Os astrócitos, o principal tipo de 
célula da glia no cérebro, estão associados à regulação homeostática deste, estando envolvidos em 
processos como a angiogénese e a regulação da barreira hematoencefálica. Num contexto de GBM, os 
astrócitos secretam fatores/proteínas que podem regular o crescimento, invasão e progressão dos 
tumores. Esta secreção astrocítica, é mediada, entre outras, pelo complexo SNARE que regula a 
exocitose, e que se encontra inibido nos astrócitos do modelo de ratinho dnSNARE. Utilizando este 
modelo, foi explorado o papel da libertação vesicular astrocítica no crescimento e invasão dos 
glioblastomas utilizando abordagens complementares. O efeito do meio condicionado (MC), derivado de 
culturas de glia provenientes de animais controlo ou dnSNARE, foi testado na viabilidade e migração de 
uma linha celular de glioma. Complementarmente, usando um modelo ortotópico de glioblastoma 
(GL261), avaliamos a influência da exocitose mediada pelo complexo SNARE em astrócitos, no 
crescimento tumoral e na sobrevivência dos animais de ambos os genótipos. Os ensaios de viabilidade 
in vitro sugerem uma regulação das células de glioma pelo MC derivado de animais controlo, aumentando 
a viabilidade destas, o que não é significativo quando utilizado o MC derivado de culturas de glia 
dnSNARE. Relativamente aos resultados in vivo, estes sugerem que as substâncias secretadas pelos 
astrócitos podem influenciar o comportamento tumoral, levando a uma menor sobrevivência dos animais. 
Interessantemente, o volume tumoral foi similar entre genótipos, sugerindo que outras características 
tumorais podem ser mediadas por esta interação entre astrócitos e GBM. Os resultados discutidos 
durante esta tese sugerem que os astrócitos, libertando moléculas reguladoras, podem contribuir para 
as características do GBM. A identificação de moléculas derivadas de astrócitos podem apontar para 
novos alvos terapêuticos, no que diz respeito ao tratamento do GBM. 
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1 Introduction 
 
In the current century, cancer remains one of the major health problems, affecting people of every 
socioeconomic status around the world. According to World Health Organization (WHO), 14.1 million of 
new cancer cases were diagnosed in 2012. Despite the advances in cancer therapies, as chemotherapy 
and radiotherapy, 8.2 million cancer deaths were accounted in 2012 (Ferlay et al., 2015). 
Cancer can be defined as uncontrolled cell growth with invasive/metastatic potential resultant from 
the accumulation of molecular alterations, such as deoxyribonucleic acid (DNA) mutations, copy number 
aberrations, chromosomal rearrangements and epigenetic modifications (responsible for gene expression 
regulation) (McLendon et al., 2008). These events are usually associated with the activation of oncogenes 
and deactivation of tumor suppressor genes. These genes are responsible for the regulation of cell 
proliferation, survival and differentiation, being necessary an alteration in both gene types for a neoplastic 
transformation. The deregulation of key signaling pathways is associated with genetic alterations 
neoplastic cells, that result in specific cancer features (e.g. proliferation, invasion, angiogenesis, etc.). In 
addition to the genetic alterations, the cellular microenvironment is also crucial for a neoplastic profile, 
where, for instance, increased secretion of growth factors can constitutively activate key pathways for cell 
proliferation (Hanahan and Weinberg, 2011). 
With the continuous growth of knowledge about cancer dynamics, it is well understood that tumors 
are not homogeneous masses of proliferating cancer cells. In fact, they are complex tissues composed 
by a large variety of cells, from parenchyma to immune cells, that together with cancer cells establish a 
large range of interactions. Thus, the advances in cancer therapeutics cannot only pass through the target 
of neoplastic cells, being necessary to understand and stop the contribution of the tumor 
microenvironment to tumorigenesis. In this scope, Hanahan and Weinberg proposed the ten cancer 
hallmarks (Figure 1.1), that include: i) evading growth suppressors; ii) avoiding immune destruction; iii) 
enabling replicative immortality; iv) tumor promoting inflammation; v) activating invasion & metastasis; 
vi) inducing angiogenesis; vii) genome instability & mutation; viii) resistance to cell death; ix) deregulating 
cellular energetics and x) sustaining proliferative signaling (Hanahan and Weinberg, 2011). 
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Figure 1.1 – The hallmarks of cancer – Cancer cells present specific capabilities that enhance tumor growth 
and metastatic dissemination (Adapted from (Hanahan and Weinberg, 2011)). 
 
1.1 Primary brain tumors  
 
The central nervous system (CNS) can present several tumor subtypes, which can be grossly 
separated in benign and malignant entities (Ostgathe et al., 2010). Tumors that have their origin in brain 
cells are classified as primary brain tumors, in contrast to cancer cells from a different origin that spread 
into the brain, commonly designated as brain metastases. Primary brain tumors present a low incidence 
between the primary tumors, only 2 %, nonetheless presented a high mortality rate (Buckner et al., 2007, 
Louis et al., 2007). 
In 2007, the WHO published its 4th edition updating the classification of CNS tumors. According to 
this manuscript, more than 100 different types were already described, regarding their origin, localization 
and histopathological features. By measuring these distinct characteristics WHO created a classification 
that grades CNS tumors in a malignant scale, being gliomas the most common form of brain tumor in 
CNS (Louis et al., 2007, Ostrom et al., 2014). An update version of CNS tumors classification was 
published this year, where for the first time, tumors were classified not only by their histological features 
but also by the distinct molecular components of tumors, resulting in the classification of new entities  
(Louis et al., 2016). 
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1.1.1 Glioma  
The origin of gliomas is still unclear, being crucial to understand how a series of molecular 
alterations that began in a couple of cells can result in a devastating disease. Nowadays, two major 
hypothesis emerge regarding glioma origin. The first one postulates that the accumulation of mutations 
and alterations in differentiated glial cells, as astrocytes or oligodendrocytes, leads to a dedifferentiation 
of those cells, acquiring a rapid proliferative and neoplastic profile. The second hypothesis, proposes that 
carcinogenic cells have their origin in progenitor undifferentiated cells, present in specific niches of the 
brain, that undergo molecular alterations resulting in neoplastic transformation (known as glioma initiating 
cells) (reviewed in Gonçalves et al., 2013). In fact, supporting this hypothesis are the glioma stem cells 
(GSC) that can be found in tumors, presenting a self-renewal capacity and high replicative potential, and 
which are able to promote the development of gliomas (Nguyen et al., 2012, Sampetrean and Saya, 
2013). For the majority of gliomas, no underlying carcinogenic have been identified, being the exposure 
to high-dose of ionizing radiation the only well-established environmental risk factor established. Although 
some epidemiological studies in glioma have been published, the data regarding other environmental risk 
factors are still inconclusive (Bondy et al., 2008, Ohgaki, 2009). 
Gliomas represent approximately 80 % of all malignant brain tumors (Ostrom et al., 2014). With 
several specific pathological and immunohistochemical characteristics, gliomas are usually classified 
considering the type of glial characteristics they present (Figure 1.2). Therefore, it is usual to separate 
gliomas in: astrocytomas (similarities with astrocytes); oligodendrogliomas (similarities with 
oligodendrocytes); oligoastrocytomas (hold mixed characteristics from astrocytes and oligodendrocytes) 
and ependymomas (present similar features to ependymal cells) (Louis et al., 2007). Considering all the 
resemblances between these cells, it is usually accepted that glioma subtypes have their origin in the 
specific glial cell subtypes or their precursors. Being one subtype of primary brain tumors, gliomas are 
also classified according to their malignancy in four distinct grades (I-IV) by the WHO. Grade I gliomas are 
designated as benign tumors with a low proliferative potential, having the possibility of cure by surgical 
resection. Tumors designated as grade II present an infiltrative nature and are already classified as 
malignant tumors although, together with grade I tumors, they are considered low grade gliomas. Usually, 
the grade II tumors progress to high grade tumors, as for example, the low-grade diffuse astrocytoma (II) 
that is able to progress to glioblastoma (IV). Grade III gliomas present histological evidences of 
malignancy, as is the case of nuclear atypia and mitotic activity. Finally, the most malignant gliomas are 
classified with grade IV and are usually associated with a rapid pre and post-operative disease evolution 
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and a fatal outcome for the patient, being designated glioblastomas (Louis et al., 2007, Ostrom et al., 
2014).  
 
 
Figure 1.2 - Classification of gliomas based in their origin and molecular characteristics – Gliomas can be 
classified considering the histological similarity to the major type of glial cells. Astrocytomas have similar 
characteristics to astrocytes and oligodendrogliomas present similar characteristics to oligodendrocytes. 
Oligoastrocytomas, have features that are present in both glial cell types.  
 
 
1.1.2 Glioblastoma (GBM) 
Glioblastoma (GBM) is the most common and malignant primary brain tumor, being the most 
common subtype of glioma (54.7% of all gliomas) (Ostrom et al., 2014). According to the WHO, GBM 
presents a grade IV classification, being represented by nuclear atypia, increased mitotic activity, 
microvascular proliferation and tissue necrosis. The tumor mass of GBM is characterized by its poor 
delineation and for having a high degree of regional heterogeneity. In the peripheral zones of the tumor it 
is common to find highly proliferating cancer cells, where the center of the tumor is mainly constituted 
by necrotic tissue (Inda et al., 2014, Hambardzumyan and Bergers, 2015). Despite being a cancer with 
low metastatic capacity, GBM is a highly invasive tumor especially along myelinated brain structures. The 
invasiveness of cells is the main reason for the poor efficacy of therapies, due to their ability to escape 
from surgical resection and radiotherapy (that target the main tumor mass) originating local recurrences 
(Louis et al., 2007). 
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 In 1940, Hans-Joachim Scherer, a pioneer in glioma research, established for the first time a 
difference between the primary and secondary GBM (Scherer, 1940). Nowadays, we known that 
approximately 90 % of GBM cases are primary, meaning that they arise de novo, usually in elderly patients 
without a clinical or histological evidence of a lower grade glioma. Patients with GBM are usually 
asymptomatic until a late course of the disease, when the first clinical signs appear (e.g. headache and 
nausea) derived from the intracranial pressure rise caused by the tumor mass size, complicating the early 
detection and treatment (Wen and Kesari, 2008). Secondary GBM represent the remaining 10 % of the 
cases, progress from lower grade astrocytomas, and manifest in younger patients presenting a better 
prognosis. Histologically, primary and secondary GBM, are virtually indistinguishable, but they present 
several differences regarding the genetic and epigenetic profile (Ohgaki and Kleihues, 2007, 2013).  
Despite the therapeutic advances over the past 20 years, the median overall survival of patients is 
only 15 months after diagnosis and treatment. In fact, all the treatments available are mostly palliative 
(Stupp et al., 2005, Wen and Kesari, 2008). The surgical resection is in the first line of treatments against 
GBM, corresponding to the resection of the maximal volume of tumor mass without putting in risk the 
CNS system activity of the patient. Usually, the surgical resection is followed by a radiotherapy treatment 
on a dose schedule of 60 Gy administered in 2.0 Gy per fraction (Malmstrom et al., 2012, Lacroix and 
Toms, 2014). Several advances in chemotherapy have also emerged in the last decade, being a standard 
treatment the use of the alkylating agent temozolomide (TMZ) in conjugation with radiotherapy (Stupp et 
al., 2005). Other therapeutics have also been used in the treatment of this disease, including 
bevacizumab, a new anti-angiogenic drug, that targets the high vascularization of these tumors by 
bindings to the vascular endothelial growth factor (VEGF), neutralizing its biological activity and leading to 
a deficient angiogenesis that slows GBM progression (Friedman et al., 2009). 
 
 
1.1.3 Glioma microenvironment  
In the recent years, the interest in glioma microenvironment has arose, and several studies showed 
the importance of parenchyma cells in the course of the pathology. There is a current recognition that 
gliomas are complex tumors composed of neoplastic and non-neoplastic cells, being virtually each type 
individually able to contribute for cancer formation, progression and or response to treatment. The 
microenvironment of glioma is usually composed by different non-neoplastic cell types including 
fibroblasts, endothelial cells and immune system cells (Hambardzumyan et al., 2015). However, the 
interaction between brain-resident and infiltrating cells in the pathology of primary and metastatic brain 
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tumors is still poorly understood (Lorger, 2012). To help understanding the complexity of glioma 
microenvironment, Hambardzumyan and Bergers proposed a compartmentalization of the tumor 
microenvironment into three anatomically distinct regions, designated tumor niches (perivascular niche 
(PVN), hypoxic niche, invasive niche; Figure 1.3). In the tumor microenvironmental niches, tumor and 
stroma cells interact via direct cell contact or paracrine signaling to ensure maintenance, growth and 
protection of tumor and cancer stem cells (Hambardzumyan and Bergers, 2015). 
The PVN presents a multicellular structure composed by several non-neoplastic cells already 
present in the brain or recruited from the periphery. The main function of this niche is to provide a 
supportive environment for cancer cells. The second GBM niche is the hypoxic niche, created by the 
abnormal vascular function in GBM, which leads to a deficient oxygen deliver within the tumor. Usually 
present in the center of the tumor mass, the niche is characterized by several necrotic areas responsible 
for the release of hypoxia inducible factors (HIF-1α and HIF-2α), leading to the expansion of GSC and the 
recruitment of innate immune cells. The last niche is usually found in more peripheral tumor zones, and 
it is designated as invasive niche. This niche is characterized by a large population of non-neoplastic cells 
that contribute to the invasiveness of glioma cells. Although astrocytes and pericytes are partially detached 
in these particular areas, it is possible to see an increased functional vasculature, that can be used to 
invade different brain areas. Moreover, it is important to understand that niches are non-static and develop 
several alterations with the course of the disease (Hambardzumyan and Bergers, 2015). Over the last 
years, studies targeting the microenvironment emerged, mostly due to the failure of treatments targeting 
the neoplastic cells. However, it is still necessary to understand how each of the different cell types 
present in the tumor can influence the disease progression.  
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Figure 1.3. - Tumor niches of Glioblastoma - Glioblastomas can present different niches, that present specific 
features and different intra-cellular composition. (A) Perivascular GBM niche – present a multicellular structure 
composed for several non-neoplastic cells (e.g. pericytes, microglia, astrocytes), providing a supportive environment 
for neoplastic cells. (B) Hypoxic GBM niche – present in the center of a tumor mass with a considerable volume, 
do not present a larger cellular diversity due to the lack of oxygen. Is usually associated for the release of factors 
that attract cells of the immune system. (C) Invasive GBM niche – similar to niche (A), also present a rich diversity 
of non-neoplastic cells, that release enhancer invasion factors. Present a rich and functional vascularization that 
can be used by glioblastoma cells to invade (Hambardzumyan and Bergers, 2015). 
 
The complex role of the tumor microenvironment in the progression of brain tumors is still poorly 
understood, and only recently the scientific field has started to decode the interaction between stromal 
and cancer cells. Microglia and macrophages have been the primary targets of new studies for their 
important immunological role and, in fact, they present a significant role in the disease progression. 
However, it is important to understand how the different components of the tumor microenvironment 
individually and collectively contribute to the tumor. In the case of primary brain tumors, astrocytes, the 
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main glial cell in the brain, can play a crucial role in the disease development. Since this project focus on 
the astrocytic modulation of GBM, the next sub-chapters will summarize the functions that have already 
been attributed to non-neoplastic cells present in the brain tumor microenvironment, and a new sub-
chapter will be dedicated to astrocytes and their relations to GBM. 
 
Microglia and tumor associated macrophages (TAMs) 
Microglia are a type of mononuclear cells that are distributed throughout the brain and act as 
immune effector cells of the CNS, being considered the resident macrophages of CNS (Hambardzumyan 
et al., 2015). In neuropathological conditions, as GBM, the blood brain barrier (BBB) is disrupted, 
resulting in an infiltration of monocytes from the periphery (Hambardzumyan et al., 2015). After entering 
the CNS, monocytes are able to differentiate into tumor-associated macrophages (TAMs), which present 
a high level of similarity with resident microglia. In fact, TAMs and microglia cells together, constitute 
approximately 30 to 40 % of the cells in GBM (Charles et al., 2011, Hambardzumyan and Bergers, 2015). 
Microglia and TAMs react to cancer cells, being these cell types already found accumulated around 
a single metastatic cancer cell, acquiring an amoeboid morphology. The migration of microglia and TAMs 
into glioma cells results from the release of chemo attractive factors by glioma cells, such as: monocyte 
chemoattractant protein-1 (MCP-1); glial-derived neurotrophic factor (GDNF) and colony stimulating factor 
1 (CSF-1). Glioma cells can also release factors that induce a shift in microglia and macrophages 
phenotype, as is the case of macrophage colony-stimulating factor (M-CSF) (Pyonteck et al., 2013). 
Macrophages can be simplistically separated based in two distinct profiles: type 1 macrophages (M1), 
that present a pro-inflammatory profile and are usually associated with the release of anti-tumorigenic 
substances; and type 2 macrophages (M2), that have an anti-inflammatory profile, presenting pro-
tumorigenic characteristics. TAMs are commonly associated with a M2 profile, although presenting some 
differences. The regulation and manipulation of this profile switch has been proposed as a possible 
therapeutic target for gliomas (reviewed in Hambardzumyan et al., 2015).  
The accumulation of microglia and TAMs in and around glioma cells results in a direct interaction 
between them, resulting in the promotion of glioma growth and invasion. In 2009, Markovic and co-
workers, established that a reduction in microglia number in a transgenic mice model, was sufficient to 
attenuate glioma growth (Markovic et al., 2009). Microglia and TAMs around the tumor present a high 
expression of stress-inducible protein 1 (STI1), which upon secretion promotes glioma growth (da Fonseca 
et al., 2014). 
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High grade gliomas are severely invasive and a large number of studies already attributed some of 
this invasive capacity to the role of microglia and macrophages. The release of factors by glioma cells, 
regulating the pro-tumorigenic profile of microglia, leads to an increase in interleukyn-6 (IL-6) secretion 
by microglia, promoting the invasive capacity of glioma cells (Saederup et al., 2010). Transforming growth 
factor-β (TGF-β) released by microglia can also increase glioma migration through a process involving 
increased integrin function and expression (Wick et al., 2001). Besides that, TGF-β induces the expression 
of matrix metalloprotease 2 (MMP2) that acts in the extracellular matrix (ECM) facilitating the glioma 
invasion (Markovic et al., 2005). In fact, a recent study showed that glioma cells release versican, an 
endogenous ligand that triggers the toll like receptor 2 (TLR2) signaling. An increased TLR2 expression is 
able to switch the microglia to a pro-tumorigenic phenotype resulting in an upregulation of matrix 
metalloprotease 9 (MMP-9) and membrane type – 1 matrix metalloproteinase (MT1-MMP), which in turn 
can lead to changes in ECM and ultimately to an increase in glioma growth and invasion (Vinnakota et 
al., 2013, Hu et al., 2014, Hambardzumyan and Bergers, 2015).  
A different population of myeloid cells that derives from circulatory monocytes, are the Tie-2 
expressing monocytes (TEMs). This subpopulation, which only accounts for approximately 7 % of blood 
mononuclear cells, has been associated with a high impact in tumor angiogenesis (De Palma et al., 2005, 
Venneri et al., 2007). Similarly to TAMs, when they reach the tumor, after crossing the BBB, they strongly 
polarize to a M2 activation state, secreting basic fibroblastic growth factor (bFGF) that induces a pro-
angiogenic activity (Lorger, 2012). More recently, it was suggested that TEMs play an important role in 
glioma anti-vascular therapies, by promoting the invasion of cancer cells after the treatment. The use of 
Bevacizumab, since 2009, an anti-VEGF agent, did not reach the level of efficacy expected. In 2016, 
Cortes-Santiago and co-workers, claimed for the first time, that TEMs can be responsible for this inefficacy. 
They suggested that using an agent against angiopoietin 2 (Ang2) combined with anti-VEGF therapy, may 
result in the improvement of the treatment and in less glioma recurrences (Cortes-Santiago et al., 2016).  
 
Endothelial cells 
The high vascularization characteristic of gliomas, has in its base the endothelial cells (EC) that 
constitute the blood vessels. These cells have emerged as critical participants in the progression of brain 
tumors, not only by allowing a constant flux of oxygen and nutrients to tumor cells, but also by the direct 
communication with glioblastoma stem cells (GSC). The secreted factors by ECs contribute to the GSC 
maintenance of their stem cell-like characteristics (Charles et al., 2011). In 2010, Charles and his co-
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workers suggested that nitric oxide released by ECs activates the Notch signaling in cancer cells, 
contributing to the maintenance of the stem cell-like state (Charles et al., 2010). Moreover, the increase 
of blood vessels or endothelial cells in orthotropic brain tumor was associated with the increase of the 
self-renewing population, resulting in a faster tumor growth (Bonavia et al., 2011). 
Endothelial cells ,together with pericytes and astrocytes, are the main cell components of BBB, a 
neurovascular unit responsible for the regulation of dynamic exchanges between bloodstream and the 
brain, giving the brain an immune-privileged position (Abbott, 2013). In primary brain tumors BBB is 
disrupted mainly by loss of properties by ECs and is responsible for the income of innate immune system 
cells in the brain that, as previously mentioned, contribute to the progression of brain cancer 
(Hambardzumyan and Bergers, 2015). 
 
Pericytes 
The strong and abnormal angiogenesis is one of the main GBM features, where is common to find 
disorganized and leaky blood vessels (Hambardzumyan and Bergers, 2015). This feature is usually 
attributed to the detachment of pericytes from the vessels, caused by the increased concentration of 
VEGF in the tumor microenvironment. Pericytes are perivascular cells with contractible capacity that 
support blood vessels and promote vascular maturation, being usually known for the control of dynamic 
processes in vasculature (Cleaver and Melton, 2003, Bergers and Song, 2005). In the context of tumor 
development, recruitment of pericytes to tumor core is crucial for structural stability and survival of 
endothelial cells. Nowadays, it is believed that glioma cells release HIF-1α, a chemoattractant for pericytes 
progenitor cells, which results in the promotion of angiogenesis and glioma neovascularization, a feature 
associated to malignant gliomas (Chekenya et al., 2002, De Palma et al., 2005). 
 
1.2 Astrocytes  
 
More than 150 years passed since Rudolf Virchow introduced for the first time the concept of 
neuroglia, which he designated as the brain connective tissue, assuming years later that the tissue “also 
contains a certain number of cellular elements” (Virchow, 1856). The second part of 19th century was 
rich in advances in cellular histology, with different glial cells being described. In 1893, Michael von 
Lenhossek proposed for the first time the term “astrocyte”, further spliced in fibrous and proplasmatic 
regarding their localization, white and grey matter, respectively (Lenhossék, 1893). Our knowledge on the 
1.Introduction 
- 13 - 
 
properties and diversity of neuroglial cells have dramatically increased. Even though, many years already 
passed and the whole range of actions in the CNS and their role on brain diseases is still far away from 
totally understood (Kettenmann and Verkhratsky, 2008). 
Defining an astrocyte is not a simple task but it has been accepted that astrocytes are 
heterogeneous cells with a star-shaped morphology, with extending numerous processes that surround 
neighbor neurons and blood vessels. The most defining characteristic of astrocytes is the expression of 
glial fibrils, known as intermediate filaments (Wang and Bordey, 2008). Perhaps, because of the lack of 
ability to form action potentials, astrocytes were for many years saw as the “ugly duck” by the scientific 
community. However, with brain research development and with several emerging functions being 
associated to these cells nowadays, thinking of astrocytes merely as neuron supporting cells is immensely 
reductive. 
In 1909, less than 20 years after astrocytes been described, Held and his team proves the ability 
of astrocytes to secret molecules that is known to be crucial for brain homeostasis (Held, 1909). 
Astrocytes have been already associated to several brain functions, being the synthesis of proteins and 
adhesion molecules that compose the ECM one of them. However, these cells are also able to synthetize 
and secrete proteolytic enzymes, as MMPs that play a vital role in ECM degradation and remodeling (Muir 
et al., 2002). Their role in angiogenesis and BBB induction and maintenance are other physiological 
aspects attributed to astrocytes action. A better understanding of angiogenesis and of the dynamics 
between astrocytes and endothelial cells (to regulate BBB stability and permeability) is critical for 
understanding the process of tumorigenesis and neurogenesis. In fact, astrocytes act as a part of a 
neuroglial secretory network, that can be defined as gliocrine system of the CNS (Vardjan and Zorec, 
2015). With a wide range of substances, some of the astroglia-derived secretory substances are: 
neurotransmitters and their precursors; hormones and peptides; eicosanoids, scavenger reactive oxygen 
species (ROS); growth factors; “plastic” factors and pathological molecules, as inflammatory factors 
(Verkhratsky et al., 2016). The release of all these substances can occur by distinct pathways, including 
diffusion through plasmalemmal pore/channels; extrusion through plasmalemmal transporters and also 
by vesicle-based exocytosis (Figure 1.4). Regarding the release by exocytosis, different vesicles have 
already been identified including: small vesicles, dense core vesicles, lysosomes, exosomes and 
ectosomes. The vesicles released by astrocytes can have different fusion events with the plasmatic 
membrane and, more importantly, different contents. The evolutionary conserved family of SNARE 
proteins are the foundation of this secretory mechanism. The family can be divided in two categories, R-
SNAREs and Q-SNAREs, being associated with the vesicular membrane or with plasma membrane 
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proteins, respectively (Jahn and Scheller, 2006). In vesicular release events, there is an increase in 
intracellular calcium (Ca2+) levels, leading to the association of vesicle proteins to membrane proteins 
(syntaxins), and to the formation of a ternary SNARE complex. The proteins of SNARE complex, namely 
synaptobrevin (VAMP), syntaxin (STX) and synaptossomal associated protein (SNAP), create a 4 α-helical 
bundle (SNAREpin), that allows the fusion of vesicular and plasma membranes (Sutton et al., 1998, 
Hamilton and Attwell, 2010, Verkhratsky et al., 2016). The SNARE complex, is not exclusive of astrocytes, 
and other brain cells like neurons also use the complex to release substances. Interestingly, Ulloa and 
his co-workers in 2015, inhibiting the SNARE protein STX1 in glioblastoma cells, showed a significant 
decrease of proliferation and invasion. This work supported the importance of autocrine signaling for 
glioblastoma cells, but also that the autocrine signaling can be targeted using the complex SNARE (Ulloa 
et al., 2015). 
 
 
Figure 1.4 - Secretory pathways and secreted substances by astrocytes -  Astrocytes present three main 
secretory pathways responsible for the release of several substances crucial for brain homeostasis. Between the 
secreted molecules is usually to found hormones and peptides, metabolic substrates, growth factors and 
inflammatory factors (Adapted from (Verkhratsky et al., 2016)). 
 
Astrocytes present a significant importance in the response to brain injuries, usually characterized 
by bleeding and an intense local inflammation. Astrocytes closely positioned to injury, respond to it 
becoming hypertrophic and forming a scar in conjugation with other brain cells (e.g. fibroblasts), that 
isolate the damaged tissue from the remaining healthy brain tissue (Cregg et al., 2014). Astrocytes near 
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the injury site not only upregulate their expression of glial fibrillary acidic protein (GFAP), but also several 
proteins and transporters, by a process known as astrogliosis (Vijayan et al., 1990, Filous and Silver, 
2016). Astrocytes are involved in several neuropathologies playing an important role in the development 
and progression of the disease. Alzheimer´s disease (AD) is a progressive neurodegenerative disease, 
characterized by the presence of amyloid beta plaques and neurofibrillary tau tangles. The main 
component of beta plaques, β-amyloid, is a neurotoxic agent that promotes the response of astrocytes 
and microglia, leading to the release of inflammation promoting mediators, potentially neurotoxic. In case 
of injury, the release of these substances is beneficial for brain damage repair, but in a case of a chronic 
disorder a constant state of activation by astrocytes and microglia leads to a chronic inflammation that 
contributes to secondary nerve damages. It is currently described that astrocytes activated by β-amyloid 
release pro-inflammatory cytokines and ROS, contribute to neuronal damage, a hallmark of AD. 
(Markiewicz and Lukomska, 2006, Filous and Silver, 2016). Interestingly, gap junctions between 
astrocytes are altered in AD, namely by the observable increase in the gap junctional protein connexin 43 
(Cx43)(Nagy et al., 1996). Moreover, gap junction proteins expression has been associated with an 
increased release of glutamate and ATP, resulting in a glutamatergic cytotoxicity, that leads to neuronal 
damages (Nakase and Naus, 2004). 
Astrocytes are also involved in other progressive neurodegenerative disorders, such as amyotrophic 
lateral sclerosis (ALS), characterized by the death of motor neurons in cerebral cortex (Vargas and 
Johnson, 2010). In ALS, astrocytes have an upregulated expression of the inflammatory cytokine 
transforming growth factor-β1 (TGF-β1), which stops microglia and T cells production of insulin-like 
growth factor 1 (IGF-1), resulting in a loss of inflammatory-mediated neuroprotection and, consequently, 
in a faster progression of the disease (Endo et al., 2015). Additionally, Parkinson´s disease (PD), 
characterized by the loss of dopaminergic neurons in the substance nigra and the presence of Lewy 
bodies (aggregates of α-synuclein), astrocytes also have an important role on the disease progression. 
The endocytosis of α-synuclein by astrocytes results in the upregulation of pro-inflammatory cytokines 
and chemokines, resulting in a constant inflammatory state prejudicial for neurons (Lee et al., 2010, 
Filous and Silver, 2016). Furthermore, astrocytes are also involved in epilepsy, where the proliferation of 
reactive astrocytes is a common feature in temporal lobe epilepsy. An astrocytic dysfunction in epilepsy, 
with alterations in channel expression and dysfunctional gap junctions, leads to an increase in the number 
of seizures and to glutamate cytotoxicity (Filous and Silver, 2016).  
The astrocytic deregulation is the basis of several brain disorders, usually contributing to a constant 
state of inflammation. Although essential for brain homeostasis, the secretory capacity of astrocytes is 
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usually altered in neurological disorders, leading to an excessive or deficient release of substances that 
disrupt the brain homeostasis. The unbalanced release of chemokines and cytokines, and also the 
disruption of gap junctions between astrocytes, have been already associated to distinct disorders 
(O’Brien et al., 2014). New therapeutic approaches targeting dysfunctional astrocytes and reducing its 
inflammatory state, can emerge in the next years. In fact, it is essential to understand not only how 
dysfunctional astrocytes contribute to several brain diseases, but also how are astrocytic mechanisms 
relevant for disease progression. In GBM, astrocytes are associated as tumor supportive cells but the 
underlying mechanisms of this support are still poorly understood. In the next chapter, a literature 
background will be presented about the interactions between astrocytes and tumor cells. 
 
1.3  Role of astrocytes in gliomas and brain metastases 
 
Since several brain cell types have an impact on the development of diseases, it is difficult to 
disclose the role of astrocytes, the major glial cell in the brain, in the disease. Despite the emerging 
studies establishing a connection between these glial cells and glioma cells, the consequences of these 
interactions remain unclear, especially in vivo. In cases of brain pathology or injury, BBB damage and 
cancer, astrocytes undergo several morphological changes being this process usually called reactive 
astrogliosis (Wilhelmsson et al., 2006, O’Brien et al., 2014). In this state, astrocytes present an 
upregulation of GFAP and vimentin, as well as several growth factors, inflammatory cytokines and ECM 
proteins. In sporadic lesion cases, the physiological alterations followed by alterations in astrocytic 
secretion can present benefits for the recovery of the brain damage (Sofroniew, 2009). However, in 
cancer, the astrocytes surrounding the cancer cells start to secrete several proteins that can help the 
growth and spread of the cancer. In fact, astrocytes and some of their secreted proteins, have already 
been proposed to enhance cancer progression (O'Brien et al., 2013). Astrocyte-derived signaling was 
reported to modulate important aspects of brain cancer progression, such as cell proliferation and tumor 
invasiveness, which are detailed below. 
Astrocytes were reported in several studies to promote proliferation of cancer cells. In vitro studies 
showed that the presence of astrocytes, astrocyte-conditioned media (ACM) or specific growth factors 
secreted by reactive astrocytes, triggers an increase in cell proliferation in different brain metastasis 
(Placone et al., 2016). Diverse molecules secreted by reactive astrocytes, as IL-6, IGF-1 or TGF-β, have 
been independently associated to a proliferation increase in different glioma cell lines (Li et al., 2010, 
Roth et al., 2010). In studies from Li and co-workers, IL-6 was responsible for an increase of 25% of cell 
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proliferation in a human glioma cell line U87MG (Li et al., 2010). In a different study, growth differentiation 
factor 15 (GDF-15), a factor upregulated in reactive astrocytes, was also able to increase cell proliferation 
(Roth et al., 2010). Besides the effects observed using glioma cell lines, astrocytes were also related with 
the proliferation of metastatic, breast and lung cancer cells. In fact, studies using these cancer cell lines 
co-cultured either with astrocytes, or exposed to ACM, present increased proliferative rates (Sierra et al., 
1997, Seike et al., 2011). A co-culture of astrocytes with lung cancer brain metastasis, leads to ERK1/2 
and AKT phosphorylation in cancer cells, both of which are important signaling pathways for cancer 
proliferation (Langley et al., 2009). Moreover, in 2015, another study showed that astrocytes presented 
a significant role in the downregulation of an important tumor suppressor gene, PTEN. Lin Zhang and co-
workers demonstrated that in the case of breast cancer brain metastases, astrocytes release microRNAs 
in their exosomes that epigenetically regulate the expression of PTEN. Interestingly, the down regulation 
of PTEN was only found in brain metastasis, demonstrating the importance of the microenvironment for 
metastasis outgrowth (Zhang et al., 2015). Although these findings support paracrine modulation, rather 
than a direct physical cell-to-cell interaction, the later should not be ruled out. 
Along with cell proliferation, migration and invasion are also important features of brain cancer, 
and are extremely relevant in the outcome of the disease. Several studies already showed that astrocytes 
are able to promote invasion and migration of glioma cell lines, and of other cancer cell lines (Placone et 
al., 2016). In 2003, a study using a glioblastoma cell line (U251), revealed that this cell line displays an 
increased invasion capacity when co-cultured with astrocytes. This effect was attributed to the activation 
of the inactive pro-MMP2 released by astrocytes. The active form of the MMP -2 is able to degrade collagen 
IV, one of the major components of ECM, facilitating the infiltration and invasion of glioma cells (Le et al., 
2003). More recently, a study using ACM showed an enhancement on the invasion potential of 
glioblastoma stem-like cells using a trans-well invasion assay (Rath et al., 2013). One of proteins secreted 
by astrocytes was IL-6, which is able to promote both growth and invasion of glioma cell lines (Li et al., 
2010). Moreover, in the last year, a study revealed that the hetero-cellular communication between 
astrocytes and glioma cells, namely through the gap junctions formed between them, are related with the 
invasion capacity of glioma cells. In fact, when a transgenic mice without Cx43 in astrocytes was used, 
perturbing the formation of hetero-cellular channels between glioma cells and astrocytes, a significant 
decrease of infiltrative edges in the tumor border was observed (Sin et al., 2016). The astrocytic effect in 
invasion of cancer cells also covers brain metastasis of different cancer types. In primary brain tumors, 
as well as in human breast and lung cell lines, matrix metalloproteinases, namely MMP-2 and MMP-9, 
are in part responsible for the astrocyte media-induced tumor cell invasion. In fact, the use of an inhibitor 
1.Introduction 
- 18 - 
 
of MMPs revealed a loss of invasive capacity of these cell lines in vitro, and a decreased capacity to form 
brain metastasis in a mice model (Wang et al., 2013). The ACM was also able to promote an increase of 
invasion on melanoma brain metastasis, where factors secreted by astrocytes appear to enhance the 
migration (Klein et al., 2015). 
Another role of astrocytes in gliomas, is their involvement in the evasion of cancer cells from the 
immune system (Hanahan and Weinberg, 2011, Placone et al., 2016). In fact, factors released by reactive 
astrocytes have a range of actions that can explain this evasion to the natural killer cells and T 
lymphocytes, immune system cells, responsible for the elimination of non-natural cells in the human body 
(Placone et al., 2016). The release of molecules by astrocytes is associated with a constitutive activation 
of STAT-3 in glioma cells, that results in a suppressive effect in the release of pro-inflammatory cytokines, 
preventing the response of T-cells. In fact, a co-culture experiment of normal human astrocytes with T 
cells resulted in a inhibitory effector function (Gomez and Kruse, 2006, Kostianovsky et al., 2008a, 
O'Brien et al., 2013). Moreover, reactive astrocytes are able to release several other immunomodulatory 
cytokines, namely IL-10. Among its several functions, IL-10 appears to be responsible for a reduction of 
antigen presentation, through a down-regulation of monocyte MHC class II expression, as well as for an 
inhibition of T-cell activity, which protects the neoplastic cells in a cancer condition (Grutz, 2005). Through 
downregulating of tumor necrosis factor alpha (TNF-α) expression, astrocytes stop the up-regulation of 
MHC II in microglia and macrophages leading to an impairment in the presentation of antigens to T-cells 
(Kostianovsky et al., 2008b). The immune protection of cancer cells provided by astrocytes, targets mostly 
the usual functions of T-cells as their activation or recruitment. Moreover the ECM glycoprotein Tenascin-
C (TNC), released by astrocytes, is responsible to mediate cell-cell and cell-matrix interactions. The role 
of ECM has been demonstrated as crucial for cancer, not only by the capacity of TNC to promote glioma 
invasion, but also to inhibit the transmigration through tumor monolayer by T-cells (Huang et al., 2010, 
Xia et al., 2016). 
 Astrocytes, have also been shown to directly protect glioma cells against different drugs, currently 
used in GBM therapeutics. For instance, the assessment of apoptosis index in glioma cells revealed a 
decrease in cell death superior to 50% upon treatment with TMZ, when the gliomas are co-cultured with 
astrocytes. Interestingly, this effect was lost when the researchers try to use ACM or a gap junction 
inhibitor suggesting that the chemo-protective effect requires a direct contact between astrocytes and 
glioma cells through connexin 43-based gap junctions (Chen et al., 2015). The same protective effect 
was also observed when cell lines of brain metastases were exposed to the chemotherapeutic agent 
paclitaxel (Taxol). The reason for this protective effect is not well understood, but processes such as the 
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uptake and retention of Ca2+ by astrocytes, or even small non coding RNAs (sRNAs) released by astrocytes, 
have already been associated to this effect in brain metastases (Lin et al., 2010, Menachem et al., 2016) 
. 
In sum, these studies attribute to astrocytes putative roles in the pathophysiology of primary brain 
tumors and brain metastases(Figure 1.5). However, the majority of these conclusions were obtained from 
in vitro studies, with obvious limitations. Taking in consideration the different cell types present in the 
brain and the interactions between them in the context of brain tumors, these studies fail to simulate the 
microenvironment complexity around the tumor. Considering that astrocytes communicate with brain 
cancer cells, it is crucial to understand the impact that these cells may have on glioma, and how the 
interaction with the surrounding cells in the tumor microenvironment in vivo can modulate disease 
progression.  
 
 
 
Figure 1.5 -  Putative roles of astrocytes in cancer progression -  Astrocytes may modulate cancer progression 
through the enhancement of tumor growth and invasion, chemoprotection, and immune escape. Several secreted 
products by astrocytes can enhance cancer progression by acting directly with neoplastic cells, or by interfering 
with the role of other non-neoplastic cells (e.g. microglia, macrophages, lymphocytes). Astrocytes can also modulate 
the extracellular matrix (ECM) conformation, presenting a direct implication in the invasion of cancer cells (Adapted 
from (Placone et al., 2016)).  
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1.4 The dnSNARE model for study of astrocyte modulation of microenvironment 
 
In order to assess the role of astrocytic vesicular release in GBM modulation in vivo, it was 
necessary to select a model with a specific impairment on this capacity. Several models in which 
astrocytes are modulated by genetic modifications, have been developed to understand the relevance of 
astrocytes in normal and diseased brain (Oliveira et al., 2015). Among them, the models in which the 
astrocytes are not able to release substances by exocytosis, such as the dnSNARE, Glast-iBot and GFAP-
TeNT, appear as good candidates for the study of astrocytes influence in GBM. The dnSNARE model was 
selected, since the dnSNARE expression in astrocytes was showed by independent studies to impact the 
release of gliotransmitters in cell culture conditions and in vivo dnSNARE mice (Zhang et al., 2004, 
Pascual et al., 2005, Sultan et al., 2015) Moreover, being an inducible model, it prevents developmental 
effects that could mask potential alterations in the brain microenvironment. The dnSNARE model has 
been selected for studies in different disorders, among which stand out the studies regarding sleep 
deprivation and the subsequent effect on cognitive/emotional processes (Halassa et al., 2009, Florian et 
al., 2011). The release of ATP by astrocytes presented an active role for sleep homeostasis. Moreover, 
studies with this transgenic model suggested that astrocytes were able to modulate epileptogenesis and 
pathophysiological consequences of epilepsy through pathways involving N-methyl-D-aspartate (NMDA) 
receptors (Clasadonte et al., 2013). The targeting of astrocytes signaling, mediated by the vesicular 
release, have been suggested to have a potential benefit for the outcome of stroke in human patients by 
limiting the spread of damage (Hines and Haydon, 2013). In conclusion, this model was validated by 
different laboratories and is highly suitable for the purpose of this project. 
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1.5 Research goals 
 
GBM are the most common and lethal tumors of the CNS, the median survival for the patients is 
approximately 15 months, with the present treatment. The current treatments available that target almost 
indiscriminately neoplastic and non-neoplastic cells have been insufficient against GBM. The role and 
importance of the glioblastoma microenvironment has been emphaticized in recent years, and future 
therapies may use the microenvironment as an additional target. Astrocytes constitute the majority of glial 
cells in the brain, and have been described to have an active role in the pathophysiology of GBM. Although 
the mechanisms are still unclear, in vitro studies, have revealed the importance of paracrine regulation 
of glioblastoma cells by astrocytes. In this work, it is hypothesized that the secreted products released in 
vesicles by astrocytes can be responsible for an influence in glioblastoma growth and invasion. To clarify 
this hypothesis, the dnSNARE mouse model that displays with an impairment in astrocytic vesicular 
release was studied. In this model, astrocytes have an impaired capacity to modulate the ECM via 
astrocytic vesicular release. Therefore, in vitro and in vivo complementary approaches were employed to 
assess whether the astrocytic modulation of the ECM via exocytosis influences GBM. We aimed to 
evaluate: 
1) The effect of conditioned medium secreted by glial cultures derived from WT and dnSNARE 
mice in viability and migration capacity of a glioma cell line; 
2) The effect of astrocytic vesicular release in tumor growth and mice survival, using an in vivo 
syngeneic orthotopic intracranial GBM model; 
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2 Materials and Methods  
 
2.1  Cell lines and culture conditions  
 
The mouse glioma 261 cell line (GL261), a kindly donation of Prof. Conceição Pedroso Lima from 
Center for Neuroscience and Cell Biology, was used in this project. In 1939, Seligman and Shear, 
obtained a carcinogenic induced mouse glioma model (GL261) through intracranial implantation of 
methylcholanthrene pellets in the brain mice, and since then this glioma model has been used in the 
study of GBM (Seligman et al., 1939, Newcomb and Zagzag, 2009). 
Cells were cultured in Dulbecco´s Modified Eagle Medium (DMEM; Gibco®, USA) supplemented 
with 10% Fetal Bovine Serum (FBS; Biochrom, UK) and 1% Penicillin-Streptomycin (Invitrogen, USA), 
which will be designated as complete DMEM from now on. Cells were maintained in a humidified 
atmosphere at 37ºC and 5% (v/v) CO2, and passaged to new flasks at sub-confluent levels. To perform in 
vitro assays, when 80% confluence was reached, GL261 cells were washed with PBS and detached with 
trypsin at 37ºC for 5 minutes. Trypsin was inactivated using complete DMEM (twice the trypsin volume), 
collected and centrifuged at 900 rpm for 5 minutes. Cells were resuspended in complete DMEM, and 
using a 1:1 dilution of trypan blue dye and cell suspension, cells were counted using a Neubauer 
chamber. Cell density was calculated accordingly with the different assays performed.  
 
 
2.2 The dnSNARE mouse model 
 
Experiments were conducted in mice expressing a transgenic dominant-negative domain of 
vesicular SNARE (dnSNARE) and their respective Wild-Type (WT) littermates were used as controls. 
Animals were obtained using crossing two transgenic mouse lines: GFAP-tTA, in which the expression of 
tetracycline transactivator (tTA) is mediated by the GFAP promoter; tetO.dnSNARE, in which the dominant-
negative domain of vesicular SNARE (Synaptobrevin II/ VAMP2), the reporter enhanced green fluorescent 
protein (EGFP) and lacZ domain are coexpressed under the control of the tetO promoter. The dnSNARE 
mice present a “Tet-Off” tetracycline transcriptional activation system where in the absence of doxycycline 
(dox) the tTA protein binds to tetO operator, triggering the transgene expression, and blocking the vesicle 
fusion (v-SNARE) with plasma membrane domain (t-SNARE; Figure 2.1). The impairment in SNARE 
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complex assembly driven by the GFAP promoter results in blockade of exocytosis specifically in GFAP+ 
cells (Pascual et al., 2005, Fujita et al., 2014, Sultan et al., 2015). 
To prevent expression of dnSNARE during mice development, doxycycline (Sigma-Aldrich) was 
administered in the drinking water (100 µg/ml), and removed 4 weeks before the experiments. Animals 
were kept in facilities with 12 h light/dark cycle with ad libitum access to food and water. 
 
 
Figure 2.1. dnSNARE model –  Schematic outlining of the “Tet-Off” system used in the transgenic model to 
impair exocytosis specifically in astrocytes (Fujita et al., 2014).  
 
 
2.3  Mouse genotyping  
 
Mice were ear tagged using a scissor, and a tail sample was collected for genotyping proposes. 
In ice, 300 µl of Cell Lysis (Citomed, Portugal) and 1.5 µl of proteinase K (200 mg/mL; Citomed, 
Portugal) were added to each sample, followed by a spin down to collect the supernatant. The samples 
were then left overnight to allow the tissue dissociation. In the next day, 100 µl of Protein Precipitation 
solution (Citomed, Portugal) were added to the cell lysis and after a quick vortex for homogenization, the 
samples were centrifuged at 14000 rpm during 5 minutes. To induce DNA precipitation, 300 µl of 
Isopropanol (100 %) were added to the samples, followed by a centrifugation (14000 rpm; 5min). The 
supernatant was carefully discarded and 300 µl of Ethanol 70 % were added to the pellet. One more 
centrifugation was done (14000 rpm; 1 min), the supernatant removed and the pellet was left to dry at 
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room temperature for 60 minutes. Finally, miliQ water was added to the samples and left to incubate at 
65ºC for 1 h.  
The genotyping was carried out by the polymerase chain reaction (PCR) technique with two pairs 
of primers, tTA and tetO, that were used in separated PCR mixtures to identify the transgenic mice. 
Additionally, the constitutive gene HSF-1 was used for control effects. The PCRs were performed in a 
thermocycler (Mastercycler®, Eppendorf, USA), and the amplified PCR products were separated on a 
1.2% agarose gel prepared in Tris-Acetate-EDTA (TAE) running buffer that was boil, before the addition of 
the green safe (2%). DNA size marker and the samples were loaded in the gel, and electrophoresis at 
150V run for 1h. Gel pictures were taken using a transilluminator (Alpha Innotech Corporation, Bio-Rad). 
The primer sequences and PCR conditions, used for genotyping are present in Table 1.  
 
Table 1 - PCR conditions for genotype identification 
Primer sequences for PCR 
Primer Sequences 
HSF-1 KO1 5´ - TCT CCT GTC CTG TGT GCC TAG C – 3´ 
HSF-1 KO2 5´- CAG GTC AAC TGC CTA CAC AGA CC – 3´ 
tTa forward 5´ - ACT CAG CGC TGT GGG GCA TT – 3´ 
tTa reverse 5´ - GGC TGT ACG CGG ACC CAC TT – 3´ 
TSL forward 5´- TGG ATA AAG AAG CTC ATT AAT TGT CA – 3 
TSL reverse 5´- GCG GAT CCA GCA ATG ATA AGA – 3´ 
 
Reaction mix components (10 µl/reaction) 
Mix/sample (µl) for tTa Mix/sample (µl) for tetO 
Buffer (NH4) SO4 10X 1 Buffer (NH4) SO4 10X 1 
MgCl2 (25mM) 1.2 MgCl2 (25mM) 1.2 
DMSO 99.9% 0.24 DMSO 99.9% 0.24 
dNTPs (10mM) 0.24 dNTPs (10mM) 0.24 
Primer tTa forward 0.4 Primer TSL forward 0.6 
Primer tTa reverse 0.4 Primer TSL reverse 0.6 
Primer HSF-1 KO2 0.3 Primer HSF-1 KO2 0.3 
Primer HSF-1 KO2 0.3 Primer HSF-1 KO2 0.3 
Taq DNA Polymerase 0.4 Taq DNA Polymerase 0.4 
H20 miliQ 5.52 H20 miliQ 5.12 
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Amplification program (40 cycles) 
Step Temperature (ºC) Duration (sec) 
Initial Denaturation 94 300 
Denaturation 94 60 
Annealing 61.6 60 
Extension 72 60 
Final extension 72 600 
 
 
  
   
2.4  Primary culture of glial cells  
 
Primary cultures of glial cells were obtained using a modified protocol of Schildge and colleagues 
(Schildge et al., 2013). Mice between 5 and 7 days’ age (P5-P7) previously genotyped were sacrificed by 
decapitation and the brain was removed and placed in a cold Hank´s Balanced Salt Solution (HBSS), to 
maintain pH and osmotic balance of the tissue. Using a magnifier, the olfactory bulbs and brainstem were 
removed and the hemispheres were separated and open. The hippocampus was carefully removed from 
both hemispheres, obtaining two cortexes that were used to follow the procedure. Meninges surrounding 
the cortical tissue were cautiously removed, to avoid contamination by meningeal cells and fibroblasts, 
and two “clean” cortex were obtained from each pup. Then, the samples from each animal were cut in 
several pieces and a quick spindown was done to pellet cortex tissue pieces. The supernatant was 
removed and 1 mL of dissociation medium (2.5 % trypsin; 87.5 % HBSS; 10 % DNase) was added per 
animal, followed by a 30 minutes’ incubation of the tissue in water bath at 37ºC. Next, a STOP solution 
(40% FBS and 60% HBSS) was added to inactivate trypsin, followed by a centrifugation at 800 rpm for 
2 minutes. After centrifugation the supernatant was discarded and 1.5 mL of complete DMEM was added 
per sample. The samples were then vigorously resuspended with a pipette until no brain tissue was visible 
at human eye. One more centrifugation was done and the medium was changed, followed by a new 
resuspension. At last, with a Neubauer chamber a sample of cell suspension plus Trypan Blue was added 
(1:1) for quantification effects. For each T25 cell culture flask, 7 x 105 cells were placed, and the medium 
(complete DMEM) was replaced after the first 48 hours, followed by a medium renovation each 3 days. 
The primary cells were left to grow for 18-20 days in an atmosphere at 37ºC supplement with 5% (v/v) 
CO2, the time necessary to reach an 80-90 % confluent state. 
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To obtain conditioned medium (CM) of glial cultures, cells in culture for 18-20 days were washed 
twice with PBS followed by another wash with DMEM without FBS. A volume of 3 mL of DMEM (1% Pen-
Strep) per T25 was added, and glial cultures were placed at an incubator at 37ºC for 24 hours. After this 
time, CM derived from WT glial cultures (CM WT) and from dnSNARE glial cultures (CM dnSNARE), were 
collected and filtered (0.2 µm), followed by a “snap freeze” in liquid nitrogen for 5 minutes. Samples 
were stored at 80ºC negative, until needed. 
 
 
2.5  Viability assays  
2.5.1 Trypan blue assay  
 
Trypan blue assay is a well described test use to determine the number of viable cells present in 
a cell suspension. The principle is based that viable cells have an intact cell membrane and are able to 
exclude the trypan blue dye, where dead cells do not, presenting thus a blue cytoplasm (Strober, 2015). 
GL261 cells were plated in 12-well cell plates at a density of 2 x 104 cells per well and allowed to adhere 
and grow in a complete DMEM for 48 hours. After this period, cells were washed twice with PBS, and 
conditioned medium (CM WT or CM dnSNARE) were added to the cells. For control effects, GL261 were 
also grown in to DMEM with 0 % FBS and DMEM with 10 % FBS. After 48 hours of CM exposure, cells 
were washed with 500 µl of PBS, followed with 200 µl of trypsin during 5 minutes at 37ºC. Trypsin was 
inactivated with 200 µl of complete DMEM, and 20 µl of cell suspension were collected to eppendorfs to 
which was added 20 µl of trypan blue solution. From this mix, 10 µl were placed in a Neubauer Chamber 
for viable cells counting effects. The results represent the mean of at least three independent experiments, 
each one in duplicate, and are normalized for the control group (0 % FBS).  
 
2.5.2 MTT assay  
 
MTT (3-(4, 5, - dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) tetrazolium reduction 
assay is a well stablished technique to analyze cell viability and metabolic cell activity. Viable cells are 
able to cleavage the tetrazolium salt MTT into formazan (blue/purple colored product), by the 
mitochondrial enzyme succinate-dehydrogenase. The quantity of formazan produced, absorbance 
recorded at 570 nm, is proportional to the number of metabolic active cells present in the sample (Slater 
et al., 1963, Denizot and Lang, 1986). GL261 cells were plated in 24-well cell plates at a density of 
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1 x 104 cells per well, and left to adhere and grow in a complete DMEM medium for 48 hours. Then, 
conditioned medium (CM WT and CM dnSNARE) were added to the attached cells for additional 48 hours. 
For control effects, GL261 were also grown in DMEM with 0 % or 10 % FBS. A solution of MTT (0.5mg 
per 1mL of PBS; Life Technologies, USA) was prepared, and 300 µl of the solution were added per well, 
followed by an incubation in a humidified atmosphere, at 37ºC and 5% (v/v) CO2, for 1 hour. MTT was 
then removed and 300 µl/well of acid-isopropanol (0.4 M of HCl in isopropanol) was added to dissolve 
the purple crystals. Finally, the absorbance at 570 nm was measured using a plate reading 
spectrophotometer (ThermoFisher scientific, USA). The results represent the mean of at least three 
independent experiments, each one in duplicate, and are normalized for the control group (0 % FBS).  
 
 
2.6  Migration assay  
 
To understand how astrocytes can contribute for the migration of glioblastoma cells in vitro, a 
Wound-Healing Assay was performed in GL261 cells exposed to CMs from WT or dnSNARE glial cultures. 
The Wound-Healing Assay, is based on observation of directional cell migration into a “wound” created 
on a cell monolayer. The assay presents a reliable way to studied directional cell migration, that is mainly 
regulated by the ECM-cell interaction and soluble factors presents in the medium (Rodriguez et al., 2005). 
GL261 cell were seeded in 12-well cell plate at a concentration of 1 x 105 cells/well, and left to 
growth in a humidified atmosphere, at 37ºC and 5 % (v/v) CO2, until a monolayer was formed. The 
“wound” was made by manual scratching with a 200 µl pipette tip, and CM from both genotypes and 
controls, were added to the cells. At this point, the “wounded” areas were photographed in 6 distinct 
places (time point: 0h), at 10x magnification using an Olympus IX51 inverted microscope equipped with 
an Olympus DP20 Digital Camera System, for quantification effects. The “wound” areas were 
photographed in the same 6 places, after 24, 48 and 72 hours of exposition to CM. The results are 
present as percentage of wound closure, and were calculated using the b-wound software. The distance 
of the wounds was measured in 10 distinct points per photo, and presented in raw pixels. The mean 
wound distance was calculated per condition in the 4 time points (0, 24, 48, and 72 hours). Wound 
closure (%) was calculated by dividing the wound distance at 24,48 and 72 hours, per the wound distance 
at 0h. The results represent the mean of at least three independent experiments, each one in duplicate, 
and are normalized for the control group (0 % FBS). 
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2.7 Intracranial orthotopic glioma models  
 
To understand the impact of the astrocytic vesicular release in glioma growth and progression an 
in vivo approach was used. The transplantation of murine syngeneic glioma cells into mice, is the best 
available approach when the tumor microenvironment is being targeted. The use of this model allows to 
mimic closely the interaction between the tumor and non-tumor cells (e.g. immune system cells) 
mimicking better the inter-cellular interactions also present in the human disease (Newcomb and Zagzag, 
2009). 
For the establishment of GBM model, GL261 glioma cells were prepared at a concentration of 
5 x 104 per 5 µl. The mice were anesthetized by intraperitoneal injection with a solution composed by 
ketamine (75 mg/kg, Imalgene 1000, Merial, USA) and medetomidine (1 mg/kg, Dorbene vet, Loetis, 
Spain). Mice were placed in a stereotaxic apparatus, where the dorsal head surface was disinfected with 
70% alcohol, and using a scalpel a small incision was done until the scalp was reached. The exposed 
area of the scalp was clean and dried, and a hole was made with a small drill at 1.8 mm medial-lateral 
right and 0.4 mm anterior-posterior from bregma. At this point, mice received a stereotactic injection of 
5 x 104 GL261 cells resuspended in 5 µl of sterile PBS, using a Hamilton syringe. The needle of the 
syringe was inserted 2.5 mm below the brain surface, and cells were slowly injected (5 µl per minute) at 
a volume of 1 µl of cell suspension each 0.5 mm depth in the brain, creating a column of GL261 cells in 
the mice brain. After the procedure, animals were sutured with 0.2 µm suture line, and atipamezol 
(1mg/kg, AntiSedan, Orion, Finland) was subcutaneously administrated for anesthesia recover. During 
this time, animals were placed under a heat lamp, and when totally awake, transferred for their respective 
cages, where they were monitored daily. 
 
2.7.1 Survival study 
 
To determine the survival of WT (n=23) and dnSNARE (n=12) mice were weighted every three days, 
and sacrificed when they presented moribund symptoms or body weight loss higher than 30%. Brain 
tissues were collected for immunohistochemistry analyses, on which samples were fixed by immersion 
in 4 % paraformaldehyde (PFA) and subsequently embedded in paraffin. 
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2.7.2 Tumor volume assessment 
 
For tumor volume measures, WT (n = 14) and dnSNARE (n = 15) were sacrificed 14 days after 
intracranial injection with 5 x 104 GL261 cells. Brain tissues were collected for immunohistochemical 
analyses, in which samples were fixed by immersion in PFA 4 % and subsequently embedded in paraffin. 
Samples were then cut using in a vibratome, in slices of 4 µm thickness in intervals of 100 µm. The 
slices were stained with Hematoxylin and Eosin (H&E), for nuclear and cytoplasmic coloration allowing 
histological characterization. Tumor cells, presenting an aberrant morphology with pleomorphic nucleus, 
were distinguishable in H&E staining. Using the AxioVision SE64 Rel.4.9.1 software (Carl Zeiss, Germany) 
the tumor area was measured in each slice, and the volume was calculated multiplying the area of tumor 
in each slice for 100 µm (distance between slices) to estimate total tumor volume across the several 
sections. 
 
 
2.8 Histological analyses  
2.8.1 Immunofluorescence  
 
Glial Cultures 
At the end of glial cultures isolation procedure, 5 x 104 cells were placed per Poly-D coated lamella. 
Immunofluorescence of glial cultures was performed 20 days after the establishment of the primary 
cultures. Glial cells were fixed using 500 µL per well of PFA (4%) for 30 minutes at room temperature 
(RT). After fixation, cells were washed three times with PBS followed by cells permeabilization with 0.3 % 
v/v Triton-X 100 in PBS for 5 minutes. Cells were then washed three additional times, and PBS with 10% 
FBS was added during 1 hour at RT to reduce unspecific ligations. Cells were washed one more time, 
and lamellas with cells were placed in humid chamber and covered with the primary antibody diluted in 
PBS with 10 % FBS for 1 hour at RT After this time the secondary antibody was added, to the cells 
previously washed, for 1 additional hour. To finalize the procedure, DAPI (1:1000; Invitrogen, USA) was 
added for 5 minutes at RT, followed by a final wash with PBS. Finally, lamellas were mounded using 
Immuno-Mount (ThermoFisher Scientific, USA) and stored at 4ºC. The specifications of antibodies used 
are listed in Table 2. 
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Brain Samples 
Brain tissue sections were deparaffinized and rehydrated by xylene and ethanol series. Samples 
were then washed with PBS, and permebialized for 10 minutes in a PBS-T (0.3%) solution. After new 
wash, a citrate buffer solution (Sigma-Aldrich, USA) was used for antigen retrieval, being the samples 
submerged in hot citrate for 20 minutes. Samples were washed one more time and PBS with 10 % FBS 
was added, to reduce unspecific bounds, for 30 minutes at RT. The samples were incubated overnight 
with primary antibodies diluted in PBS-T 0.3 % with 4 % FBS, in a humid chamber. In the following day, 
the samples were washed and incubated with the respective secondary antibodies diluted in PBS and 4 % 
FBS, for two hours at RT. In the dark, samples were washed again and incubated at RT for 10 minutes 
with DAPI (1:1000; Invitrogen, USA). The protocol ended with a new wash, and the mounting of the 
samples using Immu-mount (ThermoFisher Scientific, USA) and stored at 4ºC. For comparative effects, 
the immunofluorescence against GFP was performed in 6 brain sections per animal in the same 
conditions. Photos used to quantify immunofluorescence were acquired in the same conditions. GFP 
expression was analyzed using Fiji open source software (http://fiji.sc/Fiji) by measuring the mean gray 
value per animal, representative of the fluorescence intensity. The list of antibodies used is present in 
Table 2. 
 
Table 2 - Information about the antibodies used for immunofluorescence 
Primary Antibodies Specie Dilution Company 
anti-GFAP Rabbit 1:200 DakoCytomation, Denmark 
anti-GFP Goat 1:300 Abcam, UK 
Secondary Antibodies Specie Dilution Company 
Alexa Fluor® 594 anti-rabbit Donkey 1:1000 ThermoFisher Scientific, USA 
Alexa Fluor® 488 anti-goat Donkey 1:1000 ThermoFisher Scientific, USA 
 
  
2.8.2 Western blot  
The Western Blot (also named protein immunoblot) is a technique that allows the identification and 
separation of proteins according to their size by gel electrophoresis. The proteins are posteriorly 
transferred to a membrane and are detected by using specific antibodies (Jensen, 2012). Western Blot 
was performed in samples of brain tissues and in primary glial cultures, to identify and quantify proteins 
of interest. Brain samples were lysed in order to release the proteins of interest using a lysis buffer 
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containing: cold HEPES-buffered sucrose (0.32 M sucrose, 4 mM HEPES pH 7.4) with 25 X protease 
inhibitors, 1 % Nonidet-P40 and 0.5 % sodium dodecyl sulfate (SDS). In the case of primary glial culture 
samples, a lysis buffer containing: 50mM tris; 150mM NaCl; 2 mM EDTA and 1 % Nonidet-P40, was 
used. 
Both sample types were sonicated, and for brain tissue a centrifugation at 10000 rpm (25 minutes, 
4ºC) took place, followed by the collection of the supernatant for new eppendorfs. To determine the total 
amount of protein in each sample, the Bradford protein assay (Bio-Rad, USA) was used. The method is 
based in a colorimetric detection that should be proportional to the protein concentration present in the 
sample. The protein concentration was calculated based on a standard curve obtained with several 
dilutions of bovine serum albumin (BSA) (0.5, 1, 3, 4, 8, 10, 16 µg/ml). Samples were measured at 595 
nm in a spectrometer microplate reader (Bio-Rad, USA), and volumes corresponding to 50 µg of total 
protein were calculated. Total lysates were denatured in 2x Laemmli Buffer (Bio-Rad, USA) by heating the 
samples at 98ºC for 5 minutes. The next step was the SDS-Page step using an electric field allows the 
separation of the proteins by their molecular weight. For the “run” a 12.5 % polyacrylamide resolving gel 
was prepared, followed by the preparation of a 4 % polyacrylamide stacking gel, in which the sample were 
loaded. Electrophoresis tank was filled with a running buffer solution, and the run started at 80 V, until 
the proteins correctly enter the stacking gel, and then the voltage was increased to 120 V. The SDS-gel 
was then transferred to a nitrocellulose membrane (Trans-blot Turbo Kit, Bio-Rad, USA) using a low 
molecular weight (2.5 A, 25 V, 7 minutes) protocol. After protein transference, membranes were blocked 
for 1 hour with 5 % non-fat milk/TBS, to prevent non-specific background binding of the primary and/or 
secondary antibodies. The membranes were then incubated with primary antibodies overnight at 4ºC with 
agitation. In the next morning, the membranes were washed with TBS-T, and incubated, at RT with 
agitation during 2 hours, with the respective secondary antibodies (Table 3). After incubation period, the 
membranes were washed again in TBS-T followed by the detection of the chemiluminescent signal using 
the Clarity Western ECL substrate kit (Bio-Rad, USA), a gel blotting imaging system (Chemidoc, Bio-Rad, 
USA) and the Quantity One software (Bio-Rad, USA). The quantification of the bands was done by 
densitometry using Image Lab software (Bio-Rad, USA.) All the samples were normalized taking into 
account a loading control (α-tubulin). 
  
2.Materials and Methods 
- 35 - 
 
Table 3 - Dilutions and information about the primary and secondary antibodies used for western-blot 
analyses. 
Primary Antibodies Dilution Company 
Rabbit anti-GFAP 1:50000 DakoCytomation, Denmark 
Goat anti-GFP 1:2000 Abcam, UK 
Mouse anti-α-tubulin 1:500 DSHB, USA 
Secondary Antibodies Dilution Company 
anti-rabbit HRP 1:15000 Bio-Rad, USA 
anti-goat HRP  1:5000 Bio-Rad, USA 
anti-mouse HRP 1:15000 Bio-Rad, USA 
 
 
2.9 TCGA data meta-analysis in glioma patients  
 
The cancer Genome Atlas (TCGA) provides a powerful bioinformatics tool that can be used to 
acquire information about gene expression, copy number alterations, DNA methylation, as well as relevant 
clinical information. Currently, the dataset presents information regarding 572 GBM, 27 lower-grade 
gliomas and 10 unmatched normal samples (McLendon et al., 2008, Pojo et al., 2015). 
Clinical data from each patient included in TCGA was provided by the Biospecimen Core Resources 
(BCRs) and contain information regarding the age at diagnosis, gender, Karnofsky performance status 
(KPS), overall survival (days to death or last follow up) and treatment applied to each patient.  
The data is available for download through TCGA data matrix (http://tcga-
data.nci.nih.gov/tcga/dataAccessMatrix.htm). Gene expression data from each patient was hybridized by 
the University of North Carolina, Lineberger Comprehensive Cancer Center, using Aligen G4502A 244K 
(McLendon et al., 2008) To prevent duplicates, the median was used when the same patient presents 
more than one information regarding gene expression. The VAMP2, synaptobrevin 3 (VAMP3), 
synaptosome - associated protein 23 and 25 (SNAP23 and SNAP25), and syntaxin 1A (STX1A) expression 
values were processed. Gene expression values were categorized as high expressers for TCGA “level 3” 
values higher than average expression values for each gene independently. Moreover, the co-expression 
of the genes above was analyzed, being the high expression SNARE group, the patients with a gene 
expression higher than average expression in the five genes analyzed simultaneously. 
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2.10 Statistical analyses  
 
GraphPad Prism 6 software (GraphPad Software Inc., USA) was used to perform statistical 
analyses. Results are presented throughout as mean ± s.e.m (Standard Error Mean), and statistical 
comparisons were calculated with a 95 % confidence interval. Parametric tests were applied, since all 
data sets present Gaussian distributions. An independent t-test were applied to compare the number of 
GFAP positive cells in primary glial cultures (WT vs dnSNARE). For cell viability, and cell migration assays 
a one-way analysis of variance (ANOVA) and Tukey´s post-hoc analyses to compare the three groups 
were used (Control, CM WT, CM dnSNARE). To compare the tumor volumes of dnSNARE and WT animals, 
a one-way ANOVA was used. Regarding the effect of genotype animal in survival, a Kaplan-Meier Survival 
curve was presented, and the differences were evaluated by univariate analysis (Log-rank test). Correlation 
between GFP levels and tumor volume or survival, were assessed by Pearson correlation analyses.  
The effect of VAMP2, VAMP3, SNAP23, SNAP25 and Stx1A expression levels in the overall survival 
of GBM patients from TCGA are represented by Kaplan- Meier survival curves, and the differences were 
evaluated by a multivariate survival analysis (Cox model, adjusted for the follow putative prognostic 
factors, patient age and gender, KPS, treatment with chemotherapy and radiation). These analyses were 
made with SPSS 23.0 software (IBM, USA).
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3 Results 
 
3.1 In vitro studies  
3.1.1 Characterization of primary glial cultures 
 
To study the role of astrocytic vesicular release in glioma cells, primary glial cultures from WT and 
dnSNARE mice were stablished. The dnSNARE transgene expression in cultured astrocytes have been 
shown to reduce the number of fusion events in 91 % resulting in a drastic impairment in astrocytic 
vesicular release (Sultan et al., 2015). Primary glial cultures from both genotypes were established, and 
20 days after the isolation procedure, cultures from both genotypes reached a state of sub-confluence 
with similar cell morphology. Similar to studies that used in vitro hippocampal astrocytes (Sultan et al., 
2015), only dnSNARE primary glial cultures presented the expression of the gene reporter (EGFP) after 
20 days in culture conditions (Figure 3.1 a). To confirm the presence of astrocytes in both glial cultures, 
a western blot was performed from glial cells after 20 days in culture. Cultures derived from both 
genotypes presented the expression of astrocytic marker GFAP, confirming the presence of astrocytes 
(Figure 3.1 b). Taking into account that the dnSNARE transgene corresponds to the cytosolic portion of 
endogenous synaptobrevin II and the inexistence of functional antibodies able to discriminate between 
both proteins, the expression of GFP was measured by western-blot. As expected from other studies 
(Sultan et al., 2015), and in concordance with the fluorescence observed (Figure 3.1 a) only cultures 
derived from dnSNARE mice present GFP expression (Figure 3.1 b). Moreover, dnSNARE transgenes are 
selectively expressed in astrocytes, since EGFP co-localizes with several astrocytic markers, such as GFAP 
and S100β, and not with markers of other glial cell types or neuron markers (Fellin et al., 2009). The 
presence of GFP in our dnSNARE primary cultures, and consequently expression of dnSNARE transgene, 
confirmed that astrocytes from dnSNARE mice present a significant reduction in the number of fusion 
events and their exocytosis mediated by synaptobrevin II is significantly affected (Fellin et al., 2009, Sultan 
et al., 2015). 
Interestingly, glial cultures obtained from different dnSNARE mice present different levels of GFP 
expression (Figure 3.1 b, c). Recent studies in our group, demonstrate that dnSNARE mice express 
different levels of GFP that directly correlate with relative expression of dnSNARE and EGFP mRNA levels 
(Supplementary Figure ). Moreover, the expression of GFP, appears to correlate with diverse biological 
effects assessed at the lab. Taking in consideration that GFP levels are representative of transgene 
expression, only animals with higher levels of GFP expression were used in the following in vitro assays. 
Considering that dnSNARE model only present a vesicular impairment in GFAP positive cells, an 
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immunofluorescence against GFAP was performed in glial cultures derived from both genotypes, for GFAP 
positive cells quantification. Glial cultures derived from WT and dnSNARE mice present similar percentage 
of GFAP positive cells (Figure 3.1 d; WT, 91.4 ± 4.2 %; dnSNARE, 89.5 ± 2.1%), and no significant 
statistical differences were found (t 3 = 0.471; p = 0.670). These results indicate that the CM derived 
from glial cultures from both genotypes derived from a similar density of astrocytes, differing merely in 
the presence (dnSNARE) or absence (WT) of the transgene dnSNARE. 
 
Figure 3.1 – Characterization of primary glial cultures -  (a) Morphological characterization of glial cells after 
20 days in culture (left and middle panels), and GFP fluorescence observed only in glial cultures derived from 
dnSNARE mice (right panels). Scale bars, (left panels: 100 µm; Middle and Right panels: 50 µm) (b) Western Blot 
against GFAP and GFP in glial cells derived from WT and dnSNARE mice. (c) Levels of GFP expression in glial 
cultures derived from different dnSNARE mice. (d) Immunofluorescence against GFAP in WT and dnSNARE glial 
cultures, and quantification of GFAP positive cells percentage. Scale bars, 100 µm. Results are presented as mean 
± s.e.m.  
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3.1.2 Regulation of GL261 cells viability by astrocytic CM 
 
The glial cultures established were mainly composed by astrocytes. After confirmation of the 
transgene expression in cultures, medium with the secreted products from astrocytes was collected. The 
secreted medium from glial culture, corresponding to 48 hours of secretion, was collected and applied to 
GL261 cells, for assessing the role of vesicular secreted astrocyte products on glioma cells viability. 
Glioma cells were incubated during 48 hours with CM derived from both genotypes cultures, and cell 
viability was assessed by the trypan blue and MTT assays.   
CM derived from WT cultures lead to an increase of viable cells on glioma cells viability on the 
trypan blue assay comparing with the control group (p < 0.01). The effect was not observed when CM 
derived from dnSNARE cultures was added to glioma cells, suggesting a possible lack of secreted products 
by astrocytes. However, no significant differences were found between genotypes (F2,20 = 6.085, p = 
0.0086; Figure 3.2 a). Similar results, were obtained when GL261 metabolic viability was assessed, by 
the MTT assay. The CM derived from WT glial cultures led to an increase viability on glioma cells compared 
with control group (p < 0.5), but the effect was not observed when CM derived from dnSNARE cultures 
was applied to glioma cells (Figure 3.2 b). Although, no statistical differences were found between the 
use of CM derived from the two genotypes, the secreted products by astrocytes appear to have an 
important role in glioma cells viability (F 2,26= 4.507; p = 0.0209). Based on these findings, we postulated 
that astrocytes might increase the viability of glioma cell by paracrine regulation, via SNARE-dependent 
exocytosis. The results indicate the presence of key factors in vesicles released by WT astrocytes, that 
are able to potentiate glioma cells viability. 
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Figure 3.2 – CM derived from WT glial cultures increase glioma cells viability – Glioma cells viability 
measured by (a) Trypan Blue Assay and (b) MTT, after 48h exposed CM derived from WT glial cultures. (a) 
Quantification of viable cells (p<0.01) and (b) cell viability (p <0.05), was normalized against the control group. 
The results presented represent at least 3 independent assays, and are presented as mean ± s.e.m.  
 
 
3.1.3 Regulation of GL261 cells migration by astrocytic CM 
 
To study the role of astrocytic vesicular release in glioma cells, a wound healing assay was used in 
GL261 cells that were exposed to the CM derived from WT or dnSNARE glial cultures. The analysis of 
wound representative pictures (Figure 3.3 a) indicate that migration of GL261 cells was not affected by 
the presence of secreted substances presents in the CM. However, the migration of glioma cells was not 
progressive in groups tested, and the 20 % of wound closure observed after the first 24 hours was 
maintained after 48 and 72 hours (F 2, 36=1.105; p = 0.3421). The substances secreted by astrocytes did 
not modify the migratory profile of GL261 cells if compared with the control group at 24 hours 
(F 2, 18 = 0.1868; p = 0.8312; Figure 3.3 b). However, considering that a continuous migration over time 
was not observed in our experiences, our results were inconclusive. 
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Figure 3.3 - CM  derived from glial cultures do not affect glioma cells migration – Glioma cells migration 
measured by Wound Healing Assay. (a) Representative pictures of the wound at 24,48 and 72 hours in the three 
tested groups. Scale bars, 100 µm (b) Quantification of wound closure after 24, 48 and 72 hours in the three 
groups (control; CM WT; CM dnSNARE). The results presented represent at least 3 independent assays, and are 
presented as mean ± s.e.m. 
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3.2 In vivo studies  
3.2.1 Role of astrocytic vesicular release on mice survival  
 
Brain tumors microenvironment present a key function in the development and progression of the 
disease. The transgenic mouse model (dnSNARE) and respective controls (WT), were used to assess role 
of astrocytic vesicular release on GBM, using an orthotopic intracranial model. Mice were brain-
transplanted with syngeneic GL261 glioma cells (5 x 104), and the survival of tumor-bearing mice was 
analyzed. 
As observed in glial cultures derived from dnSNARE mice (Figure 3.1 a, b, c), and in studies at 
ICVS (Supplementary Figure ), dnSNARE mice present different levels of GFP expression indicating distinct 
levels of transgene dnSNARE expression. The GFP expression was accessed by immunofluorescence in 
each individual (Figure 3.4 a), and dnSNARE mice were separated in 2 distinct groups considering their 
GFP expression: Low GFP expressers and High GFP expressers (Figure 3.4 b). Taking in a count results 
of our group using the same transgenic model, is expected that mice with high GFP expression, also 
display a higher vesicular release impairment. The 3 groups were followed and sacrificed at an humane 
end point, and survival plotted as Kaplan-Meier survival curves (Figure 3.4 c) were evaluated. Although 
no statistical differences were found comparing the three groups, the High GFP group tend to survive 
longer than WT or even Low GFP mice (High GFP vs WT, p = 0.090; High GFP vs Low GFP, p= 0.066). 
In accordance with these findings, are the number of animals alive in each group measured intervals of 
10 days. This way, 20 days after syngeneic glioma cell injection all the animals were alive, but at day 
thirty only 39 % and 50 % of WT and Low GFP mice were alive against 100 % of the High GFP group. 
Moreover, fifty days after glioma injection only the High GFP group present animals alive (16 %) against 
all the mice found dead on the other groups (Figure 3.4 c). The same tendency is observed when 
correlated the levels of GFP presents in dnSNARE mice with their survival (p = 0.114; Figure 3.4 d). 
Despite of the lower experimental N, our results suggest that astrocytes release factors in vesicles can 
directly or indirectly modulate the disease progression, affecting mice survival. 
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Figure 3.4 – Astrocytic vesicular release impairment increases survival of GBM syngeneic orthotopic 
model survival - (a) Representative images of GFP expression in dnSNARE mice. (Scale bars, 100 µm) (b) 
Respective GFP quantification by immunofluorescence (c) Kaplan Meier survival curves and percentage of alive 
animals at days 20, 30, 40 and 50 after glioma cells injection. (d) Correlation between GFP expression in dnSNARE 
mice and overall survival of respective mice (r = 0.4802; p =0.114). 
 
 
3.2.2 Morphological assessment GBM  
 
The brains from animals previously euthanized were collected and stored for morphological 
analysis. For tumor identification on brain sections of WT and dnSNARE mice, brain tissue was stained 
with hematoxylin and eosin. The tumor developed in animals from both genotypes present similar features 
at the humane end point and was generally located in the right subcortical brain area. At that time point, 
the tumor already invaded the left brain hemisphere in all mice analyzed. In mice from both genotypes, 
glioma cells were observed at distant localizations from the injection point, demonstrating the migration 
capacity of glioma cells. It was common to find tumor cells in the ventricular system, that can be use as 
spread pathway in the brain by the tumor cells. The H&E staining allows to delimitate the tumor mass 
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from the normal brain tissue, being observed specific glioma features at the tumor localization. Tumor 
tissue presented a high nuclear density with lack of organization, presenting prominent nuclear 
polymorphism and mitotic activity. The presence of necrosis was also observed in the developed tumors 
from both mice genotypes. These specific features only present in tumor cells create a distinguishable 
tumor border, where a morphological transition from normal tumor tissue to brain parenchyma was 
observed (Figure 3.5). 
The role of astrocytes in glioma growth is yet faraway to be totally understood, but the close 
interaction between astrocytes and tumor cells is evident. To evaluate the disposition of GFAP positive 
cells, and their localization considering the tumor position, an immunofluorescence against GFAP was 
performed. The animals from both genotypes, presented similar GFAP positive distribution and was 
mainly presented around the tumor cells and in the brain parenchyma, with lower percentage of GFAP 
positive cells in tumor core. The higher levels of GFAP observed suggest the occurrence of reactive 
astrogliosis, as present in brain tumors, and a higher density of astrocytes was observed in tumor border. 
The increase nuclear density observed in the H&E staining was corroborated with DAPI, a common 
nuclear marker used in immunofluorescence. The distinguishable DAPI and GFAP staining, between 
tumor and brain parenchyma also created a distinguishable tumor border as observed on H&E staining 
(Figure 3.5). 
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Figure 3.5 Tumor developed in dnSNARE mice present typical GBM features -  Tumor formed in dnSNARE 
and WT animals, presenting common features of GBM. H&E stain of brain sections demonstrate the morphological 
differences between brain stroma and tumor tissue, creating a distinguishable border. DAPI staining reveals the 
difference at nuclear density observed in tumor tissue. GFAP can be found mainly expressed in the brain stroma 
and tumor border of the tumor, presenting a reduced expression in the tumor core. 
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3.2.3 Role of astrocytic vesicular release on glioma growth 
 
Tumor growth is a major factor for the outcome of the patients with cancer brain tumors. The 
different rates of proliferation by cancer cells between patients lead, can be the difference of months in 
patient survival. The rapid and aggressive proliferation of cancer cells, is only possible in the presence of 
distinct factors. Between them, growth factors stimulate the cellular growth and proliferation and has 
been described as overexpressed in cancer cases. In the case of primary brains tumors, cancer cells are 
able to uptake this factors that are mainly released by astrocytes. Taking the results observed in the 
survival curves into account and using the same transgenic mouse model (dnSNARE), syngeneic GL261 
glioma cells 5 x 104 glioma cells were injected intracranial and the tumor growth was accessed 14 days 
after injection.  
Animals were injected and after 14 days was observed a significant weight loss and an abnormal 
posture (ex: chromodacryorrhea; back arching in some animals) in some animals, indicating the presence 
of brain tumors. Animals were sacrificed at this time point, and brains collected for tumor identification 
and tumor volume quantification. A H&E staining was performed in animals tissue from both genotypes 
for tumor identification and delimitation (Figure 3.6 a). It was possible to observe the presence of a tumor 
mass in 80 % of the tested animals, suggesting no role of genotype in tumor development. Considering 
that dnSNARE mice present different levels of transgene expression, as previously reported, we analyzed 
the GFP expression by western-blot and divided dnSNARE mice in two main groups regarding their GFP 
expression (Figure 3.6 b). The tumor incidence or tumor formation, after 14 days, was addressed in the 
three different groups (WT; Low GFP; High GFP), presenting similar results regarding the percentage of 
animals that developed tumor at this time point (Figure 3.6 c). Brain sections with a distant between them 
of 100 µm were stained with hematoxylin and eosin, for tumor identification. The tumor volume was 
evaluated by delimitating the main tumor mass, easily distinguishable from brain parenchyma, and 
multiplying the area of tumor in each section by the sum of all the sections presenting tumor. The tumor 
volume for the different groups was calculated and no significant differences were found (F 2, 20 = 0.9158; 
p = 0.4163) indicating that astrocytic vesicular release did not present a direct impact in tumor growth 
(Figure 3.6 d). Regarding the correlation between of tumor volumes and different levels of expression in 
dnSNARE mice our data failed to link these two variables (Figure 3.6 e), supporting the idea that astrocyte-
derived molecules shall not interfere with the tumor size. The results presented suggest, that the tendency 
observed in animal survival (Figure 3.4 c) , is not related with the tumor growth but with other factors that 
directly influence the disease outcome. 
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Figure 3.6   Astrocytic vesicular release impairment does not affect in vivo GBM growth – (a) Representative 
images of H&E staining, of glioma bearing mice (WT and dnSNARE). (b) Analyses of GFP expression in dnSNARE 
mice by western-blot. Representative image of the experiment results and respective quantification. Data presented 
was normalized for α-tubulin expression. (c) Tumor incidence after 14 days in tested groups. (d) Quantification of 
tumor volume and (e) correlation with GFP expression levels in dnSNARE mice (p = 0.382; r = 0.293).  
 
 
3.3 In silico studies 
3.3.1 SNARE proteins expression in GBM patients 
 
In the dnSNARE model the VAMP2 protein is manipulated resulting in a dysregulation of the SNARE 
complex and consequently an impairment on astrocytic vesicular release. The target of a single protein 
of SNARE complex, VAMP2, leads to a dysregulation of astrocytic exocytosis. Considering that SNARE 
complex is present in several cell types, including glioma cells and astrocytes, we evaluate if a distinct 
expression of SNARE complex genes (VAMP2; VAMP3; SNAP 23; SNAP 25; STX1A) could present 
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relevance in the OS of GBM patients. The expression levels of the genes previously mentioned were 
analyzed in 389 GBM patients deposited in TCGA. 
Patients with high expression levels of STX1A (median OS = 372 days; 95 % CI = 332 - 411 days), 
presented a shorter OS when compared with patients with low expression levels of STX1A (median 
OS = 454 days; 95 % CI = 420 - 48 days; Figure 3.7 a). Using a multivariate survival analysis, with cox 
regression model, was observed an association between high levels of STX1A and a shorter OS of patients 
(Cox model p-value < 0.001), independently of other putative prognostic variables, including gender, 
chemotherapy, radiotherapy, age and KPS. The multivariate analyses confirmed that age, gender, KPS 
and radiotherapy present statistical important in the OS survival of GBM patients (Figure 3.7 b). 
Interestingly, chemotherapy did not present a significant cox model p-value, probably because of the 
discrepancy between the number of patients with and without the treatment. 
The expression of SNARE protein, VAMP2, that is targeted in dnSNARE mice, was also analyzed 
regarding the OS of GBM patients. Patients with high expression levels of VAMP2 (median OS = 404 days; 
95 % CI = 353 - 454 days), presented a similar OS when compared with low expression levels of VAMP2 
(median OS = 430 days; 95 % CI = 387 - 472 days). No association was observed between the VAMP2 
expression and the patient OS (Cox p-value = 0.305). Moreover, similar analyses were performed 
regarding the expression of three additional SNARE complex genes (VAMP3, SNAP23 and SNAP25) 
independently analyzed, but no significant association was found between the expression levels and OS 
of the patients (Supplementary Figure 2). Moreover, an analyses taking into consideration simultaneous 
the levels of the 5 SNARE proteins (VAMP2, VAMP3, SNAP 23, SNAP25, STX1A), revealed, that high 
SNARE expressers (median OS = 333 days; 95 % CI = 198 - 467 days) present a shorter OS when 
compared with low SNARE expression patients (median OS = 425 days; 95 % CI = 392 - 458 days; Cox 
p-value = 0.004; Figure 3.7). The results presented suggest clinical value regarding the expression of a 
SNARE proteins, indicating that the target of this complex can present relevance for GBM therapeutics. 
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Figure 3.7 - SNARE complex as a prognostic value in GBM patients -   (a) Kaplan Meier survival curves of 
554 GBM patients from TCGA regarding their STX1  expression levels (b) and respective multivariate survival 
analyses (cox model) (c) Kaplan Meier survival curves of 554 GBM patients from TCGA regarding their SNARE 
expression levels and respective multivariate survival analyses (cox model).(d) Multivariate analyses are adjusted 
for: gender, treatment with chemotherapy and radiotherapy, age and Karnofsky performance score (KPS) 
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4 Discussion 
 
Astrocytes are a major component of glioma microenvironment in brain parenchyma and their 
dysfunction is associated with several brain disorders. In this work, for the first time, the exocytosis 
mechanism of astrocytes was targeted, more precisely the vesicular release mediated by synaptobrevin 
II, and its impact was assessed on GBM pathophysiology. The in vitro results presented here suggest that 
astrocytes release factors that are able to increase glioma cells viability, an effect that was lost when 
astrocytes present a vesicular release impairment. Additionally, we observed that mice from both 
genotypes (WT and dnSNARE) developed tumors with similar morphological features and size. 
Interestingly, and despite of these observations, our in vivo results, suggest that mice with impaired 
astrocytic vesicular release have a better outcome in terms of survival after intracranial injection with 
glioma cells. 
The paracrine regulation of glioma cells by astrocytes was firstly described in 2003, when the use 
of ACM lead to an increase in glioma proliferation and invasion (Le et al., 2003). Another studies revealed 
that the released factors by astrocytes, such as IL-6 or IGF-1, are directly associated with increased 
proliferation of cancer cells(Sierra et al., 1997). Moreover, some of the factors up-regulated in reactive 
astrocytes have been associated with the increase in glioma cells proliferation (reviewed in Placone et al., 
2016). These results are supported by our findings, that showed an increase of glioma cells viability in 
the presence an increase in their viability in the presence of astrocytic CM. Specifically, we demonstrate 
here that this effect is only observed in the presence of CM derived from WT glial cultures when compared 
with control medium, which was not observed when used CM derived from dnSNARE glial cultures. We 
also demonstrated that it was not necessary a juxtacrine signaling by astrocytes for the increase in glioma 
cell viability, although it should not be discarded that this form of cellular communication might affect the 
results obtained. Supporting this idea, a study using lung metastatic cells identified a proliferative effect 
when lung cancer cells were co-cultured with astrocytes, but the effect was not present when they used 
ACM. Moreover, they demonstrated that astrocytes in contact with lung cancer cells change their secretory 
profile (Seike et al., 2011). A similar phenomenon is plausible to occur when astrocytes contact directly 
with glioma cells. The reactive state of astrocytes in the presence of brain injuries or cancer cells, result 
in the alteration of their secretory profile. Moreover, factors such as brain-derived neurotrophic factors 
(BDNF) that are released in dense-core vesicles by reactive astrocytes, and are diminished in CM from 
dnSNARE mice, could explain the results observed in cell viability of glioma cells (Xiong et al., 2013, 
Verkhratsky et al., 2016). Although viable cells counting and cell metabolic viability are associated with 
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cell proliferation, for a more suitable approach, a proliferative assay, as 5-Bromo-2-DeoxyUridine (BrdU) 
assay, should be performed to complement the in vitro data. Moreover, an additional complementary 
approach for this part of the work would be to target ectosomes, which are also released by astrocytes 
and contain MMPs and micro RNAs that are associated with an increased proliferation in glioma (Zhang 
et al., 2015). This approach constitutes another strategy to impair vesicular release by astrocytes, since 
our model affects mainly small and dense-core vesicles (Verkhratsky et al., 2016). 
The roles of paracrine and juxtacrine regulation of glioma invasion by astrocytes has been recently 
explored (Placone et al., 2016). The assessment of GL261 cells migration when exposed to CM derived 
from WT or dnSNARE astrocytes results were inconclusive. Indeed, this glioma cell line susceptibility to 
confluent states in the absence of serum, can explain the lack of migration along the time observed in 
our migration assay. However, different studies present an increased invasion, on different glioma cell 
lines, when exposed to ACM using distinct migration/invasion assays, such as Boyden chamber assay 
(Le et al., 2003, Rath et al., 2013). The results of these studies suggest that the ACM lead to an increase 
in glioma invasion, a hallmark of GBM. Moreover, another study, revealed that the migration capacity was 
enhanced when glioblastoma stem-like cells were co-cultured with astrocytes, comparative to ACM, 
suggesting that cell-to-cell contact can be important for glioma cells migration (Rath et al., 2013). In lights 
of our results, it would be prudent to evaluate the glioma migration by a different invasion assay, and by 
using a dynamic co-culture system of glioma cells with astrocytes. Indeed, we believe that the use of 
different glioma cell lines would elucidate the variable sensibility of these heterogeneous tumors to ACM. 
Moreover, it would also be important to understand the changes in the secretory profile of astrocytes 
when in direct contact with cancer cells, as is the case of GBM patients, to better understand the role of 
paracrine and dynamic/longitudinal regulation of glioma cells by astrocytes, and vice-versa. The invasion 
profile gains even more importance considering that the tumor location is a crucial factor in GBM patient 
survival time (Mineo et al., 2007). A recent study revealed that astrocytes were able to promote glioma 
invasion via the gap junction protein connexin 43. They demonstrated by blocking gap junctions between 
astrocytes and glioma cells, mainly composed by Cx43, that the tumors presented a lower percentage of 
infiltrative edges (Sin et al., 2016). We hypothesize that the substances released by astrocytes in vesicles 
can directly impact the glioma cells invasion, presenting a similar role to the one attributed to gap 
junctions. Moreover, a different paracrine regulation of glioma invasion by astrocytes can happen by ECM 
modulation. In the case of brain injuries (e.g. tumors), astrocytes are able to secrete a variety of 
factors/proteins that remodel the tissue around the injury (Jones and Bouvier, 2014). Interestingly, in 
brain tumors, cancer cells are able to use these changes in ECM to invade the brain parenchyma. We 
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hypothesized that the results obtained regarding dnSNARE mice survival might be due to a more restricted 
ECM, since astrocytes do not release several factors in our model that can be implicated in ECM 
remodeling. The extracellular matrix glycoprotein TNC, secreted by reactive astrocytes, is highly expressed 
in the tumor microenvironment contributing for glioma invasion (Xia et al., 2016). In dnSNARE model, 
the TNC expression can be affected resulting on lower migration and consequently higher survival. 
However, these points regarding glioma migration should be further assessed, using the brain tissue of 
glioma bearing dnSNARE mice to evaluate the infiltrative edges of tumors and the expression of proteins 
associated with glioma invasion, as MMPs, being this hypothesis merely speculative at the moment. 
 Although our in vitro results suggest a role for astrocytic vesicular release, in terms of cell viability 
modulation, the translation for in vivo approaches and mostly for clinical therapeutics may be challenging. 
The in vitro results confirm that astrocytes have the capacity to secrete molecules that regulate glioma 
cells, although secretory system of astrocytes in vivo can present several differences. Depending on the 
type of brain cells surrounding the tumor area, specific types of interactions between them and the glioma 
cells may modulate the secretory profile of the astrocytes (Pekny and Pekna, 2014). Yet, the study of 
microenvironment on in vivo models has been mainly associated with the role of TAMs on glioma 
progression, specifically for molecules released by these cells (Markovic et al., 2009, Hambardzumyan 
et al., 2015). 
Taking into account that astrocytes are the main glia cell in the brain, and their importance in 
several brain pathologies (Filous and Silver, 2016), we used a transgenic mouse model (dnSNARE) to 
explore the role of astrocytic vesicular release in GBM. Astrocytes react to the presence of neoplastic cells 
altering their morphology and secretory profile, as demonstrated by Nagashima and coworkers, where 
VEGF, MMP-2 and IL1-β were found to be strongly expressed in astrocytes around the tumor. Moreover, 
they also describe a high GFAP expression around the tumor from GBM patients, as observed in our 
histological analyses on tumor-bearing mice from both genotypes (Nagashima et al., 2002). Furthermore, 
our results indicate that the formation of tumor in the majority of the animals was independent of 
genotype, indicating that tumors had the conditions to develop even without the substances released by 
astrocytic vesicles. The features observed in our histological analyses, such as highly nuclear density and 
nuclear disorganization, are common features found in GBM patients, validating the use of our orthotopic 
model.  
The in vivo outcomes presented here suggest that an impairment in astrocytic vesicular release 
seem to result in an increased survival for dnSNARE mice. However, this association was only observed 
after the assessment of GFP expression levels in dnSNARE mice. Different expression levels of GFP were 
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found between dnSNARE mice, correlating with dnSNARE transgene expression. The GFP levels were 
used to discriminate the dnSNARE genotype in two different groups. Taking into account that this 
transgenic model works as a competitive model between the VAMP2 cytosolic tail (transgene) and the 
endogenous VAMP2 (Pascual et al., 2005), it is plausible that astrocytes with a higher transgene 
expression present a higher impairment in astrocytic vesicular release. Considering that the levels of GFP 
expression were only accessed after the experiments, and after splitting it into two groups (high and low 
expressers), we obtained a low number of dnSNARE mice per group on in vivo experiments, that may 
explain the lack of statistical significance. Therefore, future studies should consider the repetition of this 
experiment.  
Moreover, our results suggest that this survival outcome is not directly correlated with the tumor 
growth since no differences were found between tumor volume fourteen days after glioma cells injection. 
The lack of differences of tumor growth in our tumor-bearing mice can suggest possible compensatory 
mechanisms (eg increase in their secretory profile) from other non-neoplastic cells that directly interact 
with glioma cells. In fact, microglia is able to release several factors also released by astrocytes that have 
been already associated with tumor growth and invasion (Rock et al., 2004, Hambardzumyan et al., 
2015). The transgenic mouse model used in our study specifically target GFAP positive cells, however 
our results point to an insufficient role for these cells at changing the growth profile of the tumor. 
Considering that microglia is able to secrete some factors released by astrocytes, we hypothesized that a 
compensatory mechanism can occur by reactive microglia in dnSNARE mice leading to similar tumor 
volumes in mice of both genotypes. Thus, it will be interesting to further assess the distribution of reactive 
microglia in both dnSNARE and control littermates. Supporting this hypothesis are the astrocyte-microglia 
interactions observed in the brain that appear to present an important role in the biology of these cells, 
by regulating their secretory profile (Rock et al., 2004). Furthermore, we need to take in consideration 
that dnSNARE expression only inhibits exocytosis mediated by VAMP2, meaning that astrocytes are still 
able to secrete factors through vesicles associated with different fusion proteins, as is the case of Rab 
GTPases (Verkhratsky et al., 2016). Beyond that, the modulatory molecules may be released by astrocytic 
transmembrane channels, which should be intact in the dnSNARE model. Finally, we know that some 
populations of astrocytes do not express dnSNARE (Sultan et al., 2015), and those astrocytes should 
behave within the brain parenchyma as WT astrocytes. Nevertheless, despite of possible compensatory 
mechanisms, the inhibition of astrocytic vesicular release was sufficient to induce a better outcome in 
terms of survival of the transgenic animals, suggesting that exocytosis-dependent regulation of ECM may 
be critical for GBM. By targeting complementary approaches, for instance, by acting through molecular 
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mechanisms as diffusion through membrane channels or translocation by plasmalemmal transport (Zorec 
et al., 2016), might result in a more effective treatment for GBM. 
Another possible justification are the wide range of chemokine and cytokines secreted by astrocytes 
that act as immune mediators in cooperation with those produced by microglia, regulating the immune 
system at the CNS. The mechanism by which astrocytes secrete these immunological molecules is yet to 
be defined, but a release of these mediators by vesicles, similar to microglia secretion is plausible (Rock 
et al., 2004, Wang and Bordey, 2008, Claycomb et al., 2013). Although not described, it is possible that 
our dnSNARE model might have an impairment in the release of chemokines and cytokines, that are 
essential for an immune response. A critical step in the malignant progression of the tumor is the evasion 
and suppression of the host immune cells (Quail and Joyce, 2013). Several factors, that are upregulated 
in reactive astrocytes are associated with the immunosuppressive function that astrocytes can play in 
GBM. We hypothesize that the substances released in vesicles by astrocytes can have a direct role in the 
protection of tumor cells against the immune system. Considering that dnSNARE mice have an 
impairment in the release of those substances for the microenvironment, the astrocytic protective effect 
might be attenuated. Moreover, astrocytes release chemoattractant factors of TAMs that have been 
positive associated with tumor growth and invasion (Hambardzumyan et al., 2015). In fact, a recent study 
published this year demonstrated that astrocytes regulate PTEN expression in glioma cells by the release 
of microRNAs. The upregulation of PTEN result in the release of the TAMs chemoattractant CCL-2 leading 
to an increase population of microglia and TAMs around the tumor, consequently reducing the mice 
overall survival (Zhang et al., 2015). Astrocytes also secrete this chemokine by themselves (Carrillo-de 
Sauvage et al., 2012), and this feature can be compromised in our model, which might result in a lower 
infiltration by microglia and TAMs. Taking into account that the reduction of these cell types result in an 
increased survival of mice (Markovic et al., 2009), a similar phenomenon can explain the results here 
described. The assessment of TAMs and microglia population presence in our tumor-bearing mice brain 
tissue could support this hypothesis, and elucidate the in vivo results presented. 
The target of astrocytes function in brain disorders is not a novel approach in clinics. Some 
molecules have been already tested in clinical trials, targeting the astrocytes-mediated glioma uptake that 
lead to neurodegeneration in stroke and ALS (Filous and Silver, 2016). A recent promising target to 
restrain glioma growth is related with the signal cues from reactive astrocytes in the tumor 
microenvironment. In brain tumors, astrocytes express endothelin (ET), a peptide with vasoconstrictive 
properties. The activation of both ET receptors was recently associated with a protective role against 
chemotherapy, by the upregulation of anti-apoptotic proteins in cancer cells. Moreover, blocking both ET 
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receptors with macitentan, a drug currently used for pulmonary arterial hypertension, abolished the 
astrocytic protection of glioma cells against chemotherapy. The treatment resulted in an increased mice 
survival and less tumor growth of tumor-bearing mice when treated with TMZ (Kim et al., 2015). This 
study opens the door for the direct target of astrocytes in the tumor microenvironment. Our results 
regarding STX1A (a SNARE complex protein) expression on TCGA, demonstrated that high expression 
levels of this gene are associated with a poor OS of GBM patients. This finding is extremely important, 
since using human GBM samples data we found that the expression levels of one single gene involved in 
the SNARE complex formation, was enough to affect the patients’ overall survival. Takin into account that 
higher expression levels of this SNARE protein can suggest increased exocytosis, these results support 
the studies using the dnSNARE model, presented in this thesis. However, is necessary to considerer that 
mRNA levels analyzed in TCGA data base, cannot be directly associated with SNARE complex 
functionality. Moreover, the mRNA levels of STX1A are not exclusive of astrocytes, since there analyzed 
from hetero-cellular tumor samples collected from GBM patients. Although, STX1A was the only SNARE 
complex protein analyzed with prognostic value, we think that the target of a single SNARE protein, is 
enough to disrupt of the complex formation. In fact, this hypothesis is supported by the multivariate 
analyses considering the gene expression of 5 SNARE genes (VAMP2; VAMP3; SNAP23; SNAP25; 
STX1A), where the patients with a simultaneously high expression levels of the 5 genes, presented a 
shorter survival. We demonstrate here that the dysregulation of this complex could be a value target, for 
GBM treatment, considering their prognostic value. This results are supported by a Ulloa study, that reveal 
that the blockage of STX1A inhibits the glioblastoma tumor growth in a mice model (Ulloa et al., 2015), 
corroborating our data. The results presented during this thesis suggested that the target of SNARE 
complex specifically can be valid approach for the treatment of GBM. One possible approach could be 
the use of botulinum neurotoxins (BoNTs) that are currently used in the clinical to treat acute pain and 
Parkinson’s disease (Jankovic et al., 2009). This drug is a selectively inhibitor of SNARE proteins, although 
not specific for astrocytes, that result in the impairment of SNARE complex. To overcome this problem, a 
viable approach should pass by the targeting of astrocytes sub-population around the tumor, stopping 
their supportive role. The target of this population can pass by the identification of specific 
combination/configurations of SNARE protein complex that are responsible for a diversity of exocytosis 
processes (Kasai et al., 2012).  
In short, the role of astrocytes in glioblastoma can be essential for the disease progression. The 
study of astrocytes in vivo can be a challenge, due to the difficulty of targeting specifically these cells in 
models and patients. Considering that different cell types can secrete and express the same 
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proteins/genes, understanding the role of a single cell type is difficult. Here we demonstrate that a 
possible approach for the study of the cells role related to tumor microenvironment, can be performed by 
using transgenic mice models. The use of glioblastoma murine models, allows to mimic several 
interactions between the non-neoplastic cells and neoplastic cells observed in GBM patients. The 
treatment for GBM can pass by complementary approaches, of the current available treatment and the 
target of the protective role of the microenvironment.  
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5 Conclusions and Future Perspectives  
 
The results presented in this work suggest a role of the secreted molecules by astrocytic vesicles 
in GBM viability with a putative effect on tumor survival. However, the mechanisms of paracrine glioma 
regulation by astrocytes, should be further explored since the mechanisms involved in the increased of 
glioma viability observed here are still unknown at the moment. It will be interesting to characterize by 
proteomic analyses (e.g. mass spectrometry analysis), the CM derived from glial cultures obtained from 
both genotypes (WT vs dnSNARE) and assess the main glioma cell pathways that are activated/altered. 
Regarding the data presented during this thesis, a validation of our results using a distinct murine glioma 
cell line would be important. Moreover, additional functional analyses (e.g. as BrdU assay for proliferation, 
Annexin V / PI staining for apoptosis), would be a great addition to the in vitro work here presented. 
Regarding, the role of astrocytes in glioma migration, our results were inconclusive. Taking this into 
account, we propose the use of different invasion/migration assays (e.g. Boyden chamber assay) to 
confirm these results. Finally, all in vitro results were obtained using a static approach, using CM from 
glial cultures. A complementary approach with dynamic co-cultures of astrocytes with glioma cells could 
explore other possible roles of astrocytes in GBM progression, and understand the relevance of juxtacrine 
regulation of glioma cells by astrocytes.   
Regarding the in vivo approach presented on this thesis, we revealed a possible role of astrocytes 
gliotrasnmission on GBM pathophysiology. Moreover, the tissues collected in our experiment from 
dnSNARE mice should be further explored regarding the distribution of reactive microglia and TAMs, 
based on their putative role in the disease progression. The brain tissue collected could also be used for 
identification of infiltrative edges present in the tumor, exploring some of the hypothesis debated during 
the results discussion. Considering that the target of this astrocytic mechanism in patients, will be 
probably result in secondary effects, as a cognitive decline. Thus, we propose to explore this astrocytic 
inhibition using a complementary model. The use of virus with BoNTs specifically targeting astrocytes 
could support and increase the relevance of the results present during this thesis, since it would locally 
target the SNARE complex of astrocytes in a specific brain region. Finally, a micro-array analysis of tumor 
tissue derived from WT and dnSNARE mice will be relevant regarding the understanding of GBM 
mechanisms and cell pathways regulation, mediated by astrocyte exocytosis associated to VAMP2. 
It is my belief that only a multi targeting of different regulatory mechanism of GBM, including their 
microenvironment, will result in better treatments with a significantly increase on the average life 
expectancy of GBM patients. 
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7 Supplementary Information 
 
 
 
Supplementary Figure 1 – GFP reporter is a good readout of dnSNARE transgene expression - Direct 
correlation between expression levels of EGFP mRNA and dnSNARE mRNA (a), or GFP protein levels (b) measure 
in the same set of dnSNARE mice (data not published). 
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Supplementary Figure 2 - Relation between SNARE proteins and OS of GBM patients –  Kaplan Meier 
survival curves of 554 GBM patients from TCGA regarding (a) VAMP2; (b) VAMP3; (c) SNAP23 and (d) SNAP25 
mRNA expression levels, and respective multivariate analyses (adjusted for: gender, treatment with chemotherapy 
and radiotherapy, age and KPS). 
